

**MEDICINSKI  
FAKULTET**

Adresa: Kruševac bb  
81000 PODGORICA  
CRNA GORA  
Tel: +382 20 246 651  
Fax: +382 20 243 842  
url: [www.ucg.ac.me/medf](http://www.ucg.ac.me/medf)  
E-mail: [infomedf@ac.me](mailto:infomedf@ac.me)



**MEDICAL  
FACULTY**

Address: Krusevac bb  
81000 PODGORICA  
MONTENEGRO  
Phone: +382 20 246 651  
Fax: +382 20 243 842  
url: [www.ucg.ac.me/medf](http://www.ucg.ac.me/medf)  
E-mail: [infomedf@ac.me](mailto:infomedf@ac.me)

Broj: 937/10-1  
Podgorica, 30.06.2023. godine

**Univerzitet Crne Gore  
Odbor za doktorske studije  
n/r predsjedniku – prof. dr Borisu Vukićeviću**

Poštovani,

U skladu sa članom 41 i 55 Pravila doktorskih studija, i tačkom 3.8. Vodiča za doktorske studije, u prilogu akta dostavljamo obrazac D2 uz Predlog Odluke Vijeća o imenovanju Komisije za ocjenu doktorske disertacije dr pharm Gordane Stanojević, djevojačko Boljević, pod nazivom „Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju“ sa pratećom dokumentacijom.

S poštovanjem.

**MEDICINSKI FAKULTET  
V F D E K A N A,**  
Prof. dr Miodrag Radunović

## ISPUNJENOST USLOVA DOKTORANDA

OPŠTI PODACI O DOKTORANDU		
Titula, ime, ime roditelja, prezime	Dr pharm Gordana (Budislav) Stanojević, djevojačko Boljević	
Fakultet	Medicinski fakultet	
Studijski program	Farmacija	
Broj indeksa	11/17	
NAZIV DOKTORSKE DISERTACIJE		
Na službenom jeziku	Primjena odabranih tehnika 3 D štampe u izradi tableta za personalizovanu terapiju	
Na engleskom jeziku	Application of selected 3D printing techniques in the manufacture of tablets for personalized therapy	
Naučna oblast	Farmacija- Farmaceutska tehnologija	
MENTOR/MENTORI		
Prvi mentor	Prof.dr Svetlana Ibrić	Farmaceutski fakultet Univerziteta u Beogradu Farmaceutska tehnologija
KOMISIJA ZA PREGLED I OCJENU DOKTORSKE DISERTACIJE		
Prof.dr Zorica Potpara, vanredna profesorica	Medicinski fakultet Podgorica Univerzitet Crne Gore	Farmaceutska tehnologija
Prof dr Svetlana Ibrić, redovna profesorica	Farmaceutski fakultet Univerziteta u Beogradu	Farmaceutska tehnologija
Prof.dr Nataša Duborija Kovačević, redovna profesorica	Medicinski fakultet Univerziteta Crne Gore	Farmakologija i toksikologija
Datum značajni za ocjenu doktorske disertacije		
Sjednica Senata na kojoj je data saglasnost na ocjenu temu i kandidata	12.03.2020.godine	
Dostavljanja doktorske disertacije organizacionoj jedinici i saglasnost mentora	19.05.2023.godine	
Sjednica Vijeća organizacione jedinice na kojoj je dat predlog za imenovanje komisija za pregled i ocjenu doktorske disertacije	30.06.2023.	
ISPUNJENOST USLOVA DOKTORANDA		
U skladu sa članom 38 Pravila doktorskih studija kandidat je dio sopstvenih istraživanja vezanih za doktorsku disertaciju publikovao u časopisu sa (SCI/SCIE)/(SSCI/A&HCI) liste kao prvi autor.		
Spisak radova doktoranda iz oblasti doktorskih studija koje je publikovao u časopisima		

**sa SCI /SCIE .**

Gordana Stanojević , Đordije Medarević, Ivana Adamov , Nikola Pešić , Jovana Kovačević , Svetlana Ibrić. *Tailoring Atomoxetine Release Rate from DLP 3D-Printed Tablets Using Artificial Neural Networks : Influence of Tablet Thickness and Drug Loading.* *Molecules* 2021, 26.111 .

[Https// doi.org/10.3390/molecules26010111](https://doi.org/10.3390/molecules26010111)

Impak faktor : 3,267


**Obrazloženje mentora o korišćenju doktorske disertacije u publikovanim radovima**

Dio istraživačkog materijala koji proističe iz doktorske disertacije, a koji se odnosi na optimizaciju formulacije i uslova štampanja DLP 3D tehnikom, kao i uspostavljanje korelacije i mogućnosti predviđanja brzine rastvaranja ljekovite supstance iz 3D štampanih tableta primjenom vještačkih neuronskih mreža, publikovan je u vidu rada 2021. godine u renomiranom međunarodnom časopisu *Molecules* 2021, 26.111 . [https// doi.org/10.3390/Molecules26010111](https://doi.org/10.3390/Molecules26010111), koji je indeksiran u SCIE listi , **impakt faktor 3.267.**

Nezavisna, usko specijalizovana recenzentska komisija je ovo istraživanje ocijenila kao veoma aktuelno i inovativno, od interesa za sveukupnu naučnu javnost, što je potvrda naučnog doprinosa rezultata doktorske disertacije.

**Datum i ovjera (pečat i potpis odgovorne osobe)**

U Podgorici ,  
(30.06.2023)



VF DEKANA  
Prof.dr Miodrag Radunović

**Prilog dokumenta sadrži:**

1. Potvrdu o predaji doktorske disertacije organizacionoj jedinici
2. Odluku o imenovanju komisije za pregled i ocjenu doktorske disertacije
3. Kopiju rada publikovanog u časopisu sa odgovarajuće liste
4. Biografiju i bibliografiju kandidata
5. Biografiju i bibliografiju članova komisije za pregled i ocjenu doktorske disertacije sa potvrdom o izboru u odgovarajuće akademsko zvanje i potvrdom da barem jedan član komisije nije u radnom odnosu na Univerzitetu Crne Gore

UNIVERZITET CRNE GORE

MEDICINSKI FAKLTET

Broj: 736/1-1

Podgorica 19.05.2023. godine

## POTVRDA

Potvrđuje se da je dr pharm Gordana Stanojević ,djevojačko Boljević predala 7 primjeraka doktorske disertacije, pod nazivom „ **Primjena odabranih tehnika 3D štampe u izradi tablete za personalizovanu terapiju** “ dana 19.05.2023.godine .

Potvrda se izdaje u svrhu pregleda i ocjene doktorske disrtacije.

ŠEF STUDENTSKE SLUŽBE  
*Sonja Vukićević*  
Sonja Vukićević, diplomirani pravnik



**UNIVERZITET CRNE GORE**  
**MEDICINSKI FAKULTET**  
**Broj: 937/10**  
**Podgorica, 30.06.2023. godine**

Na osnovu člana 64 stav 1 tačka 9 Statuta Univerziteta Crne Gore, (Bilten UCG br.337/2015 i br 447/2018), člana 41 i 55 Pravila doktorskih studija, inicijalnog predloga Komisije za doktorske studije Medicinskog fakulteta broj: 736/1 od 14.06.2023 godine i tačke 3.8 Vodiča za doktorske studije Univerziteta Crne Gore, Vijeće Medicinskog fakulteta na elektronskoj sjednici održanoj 29-30.06.2023. godine, donijelo je

#### **ODLUKU**

##### **I**

Kandidat dr pharm Gordana Stanojević, djevojačko Boljević, ispunjava formalne uslove za ocjenu doktorske disertacije: „**Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju**“.

##### **II**

Predlaže se Komisija za ocjenu doktorske disertacije dr pharm Gordane Stanojević, pod navedenim nazivom: „**Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju**“ u sastavu:

1. **Prof. dr Zorica Potpara**, vanredna profesorica Medicinskog fakulteta Univerziteta Crne Gore, naučna oblast: farmaceutska tehnologija;
2. **Prof. dr Svetlana Ibrić**, redovna profesorica Farmaceutskog fakulteta Univerziteta u Beogradu, naučna oblast: farmaceutska tehnologija;
3. **Prof. dr Nataša Duborija Kovačević**, redovna profesorica Medicinskog fakulteta Univerziteta Crne Gore, naučna oblast: farmakologija i toksikologija;

##### **III**

Komisija za ocjenu doktorske disertacije je dužna da Vijeću Medicinskog fakulteta, podnese izvještaj koji sadrži ocjenu doktorske disertacije.

#### **Obrazloženje**

Dr pharm Gordana Stanojević je predala doktorsku disertaciju pod nazivom: „**Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju**“ dana 19.05.2023. godine.

Vijeće Medicinskog fakulteta je utvrdilo da kandidat ispunjava uslove iz člana 38 Pravila doktorskih studija, da kandidat dr pharm Gordana Stanojević ima, kao prvi autor jedan rad sa rezultatima iz teze objavljen u časopisu sa SCI/SCIE liste. Samim tim su se stekli uslovi da se imenuje Komisija za ocjenu pomenute doktorske disertacije. Na osnovu svega navedenog, odlučeno je kao u dispozitivu ove Odluke.

**VIJEĆE MEDICINSKOG FAKULTETA**  
**PREDSJEDAVAJUĆI,**

**Prof. dr Miodrag Radunović, v.f. dekana**

Article

# Tailoring Atomoxetine Release Rate from DLP 3D-Printed Tablets Using Artificial Neural Networks: Influence of Tablet Thickness and Drug Loading

Gordana Stanojević<sup>1</sup>, Djordje Medarević<sup>2</sup>, Ivana Adamov<sup>2</sup>, Nikola Pešić<sup>2</sup>, Jovana Kovačević<sup>2</sup> and Svetlana Ibrić<sup>2,\*</sup>

<sup>1</sup> Institute for Medicines and Medical Devices of Montenegro, Ivana Crnojevića 64a, S1000 Podgorica, Montenegro; gordana.boljevic@cinmed.me

<sup>2</sup> Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia; djordje.medarevic@pharmacy.bg.ac.rs (D.M.); ivana.adamov@pharmacy.bg.ac.rs (I.A.); nikola.pesic@pharmacy.bg.ac.rs (N.P.); Jovana.Kovacevic@hemofarm.com (J.K.)

\* Correspondence: svetlana.ibric@pharmacy.bg.ac.rs; Tel.: +381-11-3951-371

check for updates

**Citation:** Stanojević, G.; Medarević, D.; Adamov, I.; Pešić, N.; Kovačević, J.; Ibrić, S. Tailoring Atomoxetine Release Rate from DLP 3D-Printed Tablets Using Artificial Neural Networks: Influence of Tablet Thickness and Drug Loading. *Molecules* **2021**, *26*, 111. <https://doi.org/10.3390/molecules26010111>

Academic Editor: Derek J. McPhee

Received: 8 December 2020

Accepted: 24 December 2020

Published: 29 December 2020

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Various three-dimensional printing (3DP) technologies have been investigated so far in relation to their potential to produce customizable medicines and medical devices. The aim of this study was to examine the possibility of tailoring drug release rates from immediate to prolonged release by varying the tablet thickness and the drug loading, as well as to develop artificial neural network (ANN) predictive models for atomoxetine (ATH) release rate from DLP 3D-printed tablets. Photoreactive mixtures were comprised of poly(ethylene glycol) diacrylate (PEGDA) and poly(ethylene glycol) 400 in a constant ratio of 3:1, water, photoinitiator and ATH as a model drug whose content was varied from 5% to 20% (*w/w*). Designed 3D models of cylindrical shape tablets were of constant diameter, but different thickness. A series of tablets with doses ranging from 2.06 mg to 37.48 mg, exhibiting immediate- and modified-release profiles were successfully fabricated, confirming the potential of this technology in manufacturing dosage forms on demand, with the possibility to adjust the dose and release behavior by varying drug loading and dimensions of tablets. DSC (differential scanning calorimetry), XRPD (X-ray powder diffraction) and microscopic analysis showed that ATH remained in a crystalline form in tablets, while FTIR spectroscopy confirmed that no interactions occurred between ATH and polymers.

**Keywords:** three-dimensional (3D) printing; additive manufacturing; digital light processing (DLP); personalized therapy; neural networks; optimization; release rate

## 1. Introduction

Three-dimensional (3D) printing, also known as additive manufacturing, is a process which enables the production of solid objects of practically any shape by digitally controlled deposition of materials in a layer-by-layer manner [1]. After approval of the first 3D-printed medicine Spritam<sup>®</sup> (Aprecia Pharmaceuticals) by the United States Food and Drug Administration (FDA) in 2015 [2], this technology, used in various fields of industry, has attracted huge attention from the professional and scientific public, showing the potential to revolutionize the pharmaceutical field and the way medicines are designed and produced [3,4].

The concept of personalized medicine seeks to tailor medical treatment to the individual need of each patient based on their own characteristics, needs and state of disease, in order to achieve the most desirable therapeutic outcomes [5]. One of the most important aspects of personalized medicine is individualization and adjustment of the dosage to a single patient. Traditional large-scale manufacturing processes are not offering many

possibilities to implement this concept, because medicines are usually produced in a limited number of doses, which do not exactly match the need of each patient. This is particularly an issue in the field of solid dosage forms, where splitting or crushing of tablets is the only way to adjust the dose, which can result in an inadequate quantity of medicine or violation of the function of the film coating when it has the role of modifying the release rate of the active substance [6]. On the other hand, the application of 3D printing in the pharmaceutical industry could make it possible to move from a “one size fits all” approach to the manufacturing of small batches of patient-tailored medicines [7–9], as it allows flexible adjustment of the dose, appropriate release profiles and a combination of drugs in a single polypill [10–14].

Various types of printing technologies have been used so far in the manufacturing of dosage forms, including fused deposition modelling (FDM), based on material extrusion [15,16], selective laser sintering (SLS), based on the laser binding of powder particles [17,18], and stereolithography (SLA) and digital light processing (DLP), based on polymerization and solidification of a photocurable resin which contains the active substance upon light irradiation [19]. While SLA uses a laser beam to cure the layers, DLP uses a digital light projector to gradually expose and cure the whole layer of photopolymerizable resin simultaneously [20,21]. After printing each consecutive layer, the moving platform immerses into the resin tank, covering previously cured layers with photocurable resin, enabling each following layer to be cured by the light source and to adhere to the previous one, until the printing of the object is completed. Compared to other 3D-printing techniques, SLA and DLP are fast, produce objects with high printing resolution and accuracy, and also prevent drugs from thermal degradation as heating is minimized. On the other hand, the main disadvantage is that there are a limited number of photocrosslinkable polymers that can be used in preparing photoreactive mixtures, as well as the fact that they are currently not on the generally recognized as safe (GRAS) list [21].

So far, DLP printers have demonstrated their capacity to create dental models with high accuracy [22], as well as patient-specific drug delivery devices, including microneedle arrays on finger splints [23], hydrogel microneedles [24], non-dissolving suppository molds [25] and various implants [26]. Despite numerous advantages, the potential application of the DLP technique in the production and optimization of oral dosage forms has not been fully explored. Kadry et al., for the first time, assessed the feasibility of DLP 3D printers in the fabrication of solid oral dosage forms, using poly(ethylene glycol) diacrylate (PEGDA) and poly(ethylene glycol) dimethacrylate (PEGDMA) as photoreactive polymers and theophylline as a model drug [27]. After optimization of various printing parameters including UV intensity, exposure time, layer thickness and polymer concentration, various types of modified-release tablets with or without perforation were printed. Madzarevic et al. prepared 11 formulations of ibuprofen tablets following the D-optimal mixture design from Design Expert software. Two artificial neural networks (ANN) (STATISTICA 7.0 and MATLAB R2014b) were used in order to investigate how the formulation factors affect the printability, as well as to predict and optimize extended ibuprofen release from printed formulations. This study described that appropriate ANN allows understanding of the input–output relationship in DLP printing of pharmaceuticals [28]. Krkobabic et al. investigated the effect of three different hydrophilic excipients on the paracetamol release rate from DLP-printed tablets, with the aim to improve the very slow and incomplete drug release from tablets produced by DLP technology. The study demonstrated that the addition of mannitol, sodium chloride and poly(ethylene glycol) 400 (PEG 400) increased paracetamol release from printed tablets, with a different effect on mechanical characteristics of tablets [29]. In another study, Krkobabic et al. demonstrated successful DLP printing with an active substance suspended in photopolymer mixture [30]. In a study by Larush et al., pH-responsive hydrogels loaded with sulforhodamine B were produced using DLP 3D printing [31]. Printed hydrogels showed high swelling and faster drug release at higher pH, which could be particularly useful for targeted drug release in the small intestine. Oral

dosage forms fabricated with DLP 3D printing, providing immediate release of the active substance, have not been yet described in the literature.


Artificial neural networks are one of the main tools used in machine learning; they are brain-inspired systems which are intended to replicate the way that humans learn. Neural networks consist of input and output layers, as well as a hidden layer (one or more), consisting of units (often called “neurons” or “nodes”) that transform the input into something that the output layer can use. There are several types of networks, which have specifics and differ in architecture and learning algorithms. Likewise, one chosen type of a network can differ in the number of layers, the number of neurons in each layer, the number of epochs used for learning, as well as the type of functions used (activation and postsynaptic function). ANNs have been used in pharmaceutical development for the last twenty years, mainly in formulation and process optimization. The advantage of ANN over statistical techniques, such as Design of Experiments (DoE) using multiple regression analysis, is the ability to simultaneously model, optimize and predict a large number of variables. Furthermore, ANNs can handle incomplete, missing data or those whose structure is not predefined [32].

The aim of this study was to develop ANN predictive models for atomoxetine hydrochloride (ATH) release rates from DLP 3D-printed tablets. Moreover, our aim was to examine the possibility of tailoring drug release rates from immediate to prolonged release by varying the tablet thickness and the drug loading. ATH was chosen as a model drug because it is used in the wide range of doses (500 micrograms/kg daily to 100 mg or 1.4 mg/kg daily) mostly within the child population in the treatment of attention deficit hyperactivity disorder (ADHD) [33], which makes it a suitable candidate for individualization of therapy.

## 2. Results and Discussion

### 2.1. 3D-Printing Process

Cylindrical tablets of constant diameter but growing thickness, containing different amounts of ATH, were successfully fabricated using a DLP 3D printer (Figure 1).



**Figure 1.** Schematic illustration of the DLP (digital light processing) printing process and obtained tablets of 1 mm, 2 mm and 3 mm thickness.

The printing process was fast and efficient and lasted from 4 min 30 s to 13 min 30 s for 20 tablets of each formulation, depending on the thickness of the tablets. This confirms previously reported advantages of DLP 3D printers in terms of the ability to fabricate a bulk amount of tablets in a short period of time at room temperature [27–29], making it possible, together with other 3D-printing technologies, to be used within clinical settings and community pharmacies for the preparation of customized dosage forms and medical devices [34,35].

To date, DLP printers have been exploited to produce tablets and hydrogels containing different drugs, e.g., ATH [30], theophylline [27], ibuprofen [28], paracetamol [29] and sulforhodamine B [31], polymers/mixtures of polymers, including PEGDA, PEG 300 and PEG 400, and photoinitiators (PI) such as Irgacure 2959, riboflavin and diphenyl (2,4,6-



trimethylbenzoyl) phosphine oxide (DPPO). Unlike commercially available resins, when it comes to the printing of the dosage forms, it is necessary to establish optimal printing parameters for each formulation separately, in order to ensure good adhesion of the tablets to the building platform and to avoid significant variations in tablet dimensions and consequently drug loading [14,28].

The working wavelength of the Wanhao Duplicator 8 3D printer used in this study is 405 nm. The same working wavelength was used in our previous studies, where the model drugs were ibuprofen [28] and ATH [30]. Both of the studies demonstrated that no drug degradation occurred during the 3D-printing process. The stability of the drug upon UV light irradiation is an important issue and it has to be evaluated while considering the feasibility of DLP 3D-printing technology for preparation of tablets with a particular drug substance.

## 2.2. Appearance, Weight, Dimensions and Drug Content

All of the fabricated tablets had a smooth surface and were of uniform shape in accordance with the developed 3D model (Figure 2). Tablets were stored at ambient conditions and did not show signs of changes in consistency and shape.




Figure 2. Fabricated tablets containing 15% ATH (atomoxetine hydrochloride) with diameters of 8 mm and 2 mm thickness.

The measured weight, dimensions and drug content of all formulations are shown in Table 1.

ATH is approved for use in children aged 6 years and older in the treatment of ADHD [33] and is marketed in the form of tablets and capsules within a wide range of doses: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg [36]. Most of the studies that aimed to demonstrate the feasibility of various 3D-printing techniques in the fabrication of pharmaceutical dosage forms have been conducted with a clinically irrelevant amount of drugs. The influence of differences in surface area of tablets on drug-release behavior has already been investigated and described in papers published in the field of DLP 3D-printing research [27]. In the present study, by varying the thickness of the tablets and the amount of drug in the photoreactive mixture from 5% to 20%, we have managed to fabricate series of tablets with the content of ATH within its therapeutic range. This confirmed the potential application of DLP 3D-printing technology in the individualization of therapy by producing tablets with different drug loadings, which would enable adjustment of dosage to the need of each particular patient by taking tablets individually or in combination. Furthermore, the smallest amount of drug incorporated into the fabricated tablets was around 2 mg, indicating the potential for fabrication of low-dose medicines. In a study by Bracken et al. conducted among children aged 4–12, tablets with a diameter of 8 mm were rated to be the most acceptable tablet size; also, beside tablet size, as the second most

important factor, if they had to take tablets every day, the participants reported taste of the tablets [37]. Taking into account that the size and taste of a tablet are fundamental to the ability and willingness of a child to swallow it, small tablets that can be fabricated with the DLP 3D printer containing a fraction of the required dose may be considered as a solution to improve both the acceptability and adequate dosing. As ATH was used as a model drug, which is mainly indicated in children for the treatment of ADHD, the diameter of the tablet was constant at 8 mm, while the thickness of the tablets varied, thus achieving different drug loadings and release profiles. Masking the unpleasant taste of a drug is another issue which can be overcome by adding taste-masking substances or natural sweeteners like mannitol, whose suitability for DLP printing has already been demonstrated by Krkobabic et al. [29].

**Table 1.** Measured weight, diameter, thickness and drug content (mean  $\pm$  SD).

Formulation	Weight (mg)	Diameter (mm)	Thickness (mm)	Drug Content (mg)
D5-1.00	35.01 $\pm$ 2.90	7.88 $\pm$ 0.22	0.92 $\pm$ 0.10	2.06 $\pm$ 0.04
D5-1.25	54.30 $\pm$ 8.80	7.97 $\pm$ 0.07	1.25 $\pm$ 0.04	2.44 $\pm$ 0.05
D5-1.50	70.50 $\pm$ 5.40	8.02 $\pm$ 0.04	1.48 $\pm$ 0.03	3.14 $\pm$ 0.01
D5-1.75	84.93 $\pm$ 6.50	8.05 $\pm$ 0.06	1.75 $\pm$ 0.02	4.15 $\pm$ 0.20
D5-2.00	110.38 $\pm$ 14.80	8.22 $\pm$ 0.38	1.90 $\pm$ 0.20	4.62 $\pm$ 0.15
D5-3.00	215.80 $\pm$ 15.60	8.62 $\pm$ 0.32	2.93 $\pm$ 0.09	7.76 $\pm$ 0.20
D7.50-2.50	116.22 $\pm$ 6.10	8.14 $\pm$ 0.21	2.43 $\pm$ 0.04	7.16 $\pm$ 0.02
D10-1.00	45.12 $\pm$ 2.00	7.96 $\pm$ 0.11	0.98 $\pm$ 0.03	3.71 $\pm$ 0.03
D10-1.25	65.57 $\pm$ 8.03	8.03 $\pm$ 0.04	1.25 $\pm$ 0.06	5.06 $\pm$ 0.05
D10-1.50	85.97 $\pm$ 10.20	8.10 $\pm$ 0.09	1.50 $\pm$ 0.02	6.41 $\pm$ 0.09
D10-2.00	94.35 $\pm$ 5.80	8.08 $\pm$ 0.10	1.96 $\pm$ 0.08	7.18 $\pm$ 0.06
D10-3.00	188.15 $\pm$ 15.6	8.21 $\pm$ 0.12	2.92 $\pm$ 0.15	12.84 $\pm$ 0.50
D12.50-1.50	78.89 $\pm$ 7.20	8.29 $\pm$ 0.24	1.44 $\pm$ 0.06	8.47 $\pm$ 0.40
D15-0.75	40.11 $\pm$ 6.40	8.04 $\pm$ 0.07	0.77 $\pm$ 0.03	5.20 $\pm$ 0.03
D15-1.00	49.89 $\pm$ 8.10	8.11 $\pm$ 0.11	1.02 $\pm$ 0.09	6.37 $\pm$ 0.03
D15-1.50	95.39 $\pm$ 9.20	8.33 $\pm$ 0.17	1.48 $\pm$ 0.04	11.72 $\pm$ 0.03
D15-2.00	111.84 $\pm$ 14.60	8.30 $\pm$ 0.19	1.96 $\pm$ 0.10	15.15 $\pm$ 0.80
D15-3.00	207.53 $\pm$ 29.20	8.87 $\pm$ 0.31	2.95 $\pm$ 0.08	33.16 $\pm$ 0.75
D20-0.75	48.10 $\pm$ 5.40	8.22 $\pm$ 0.17	0.78 $\pm$ 0.03	8.10 $\pm$ 0.50
D20-1.00	54.29 $\pm$ 5.10	8.02 $\pm$ 0.06	1.01 $\pm$ 0.04	9.05 $\pm$ 0.74
D20-1.50	110.14 $\pm$ 6.80	8.47 $\pm$ 0.09	1.51 $\pm$ 0.06	18.14 $\pm$ 0.23
D20-2.00	118.03 $\pm$ 10.60	8.40 $\pm$ 0.33	1.95 $\pm$ 0.08	21.20 $\pm$ 0.58
D20-3.00	214.35 $\pm$ 18.20	9.02 $\pm$ 0.26	2.94 $\pm$ 0.09	37.48 $\pm$ 1.41

The diameter of the fabricated tablets varied to a greater extent with respect to their thickness, especially with the increase of the amount of ATH in the formulations. This can be explained by the larger amount of suspended particles and their scattering phenomena onto the light beam [30]. Additionally, greater variation in diameter in comparison to the designed 3D model was observed for 2-mm- and 3-mm-thick tablets, which can be attributed to the longer exposure time needed for their successful printing. Therefore, it is very important to set the exposure time to the smallest value that enables solidification in order to minimize the impact on the dimensions of the tablets and consequently avoid dosage variation.

### 2.3. Mechanical Properties of Tablets

Since quality assessment guidelines for 3D-printed medicines have not been established yet, and some of the traditional testing methods are not entirely suitable for their control due to the differences in consistency and firmness in comparison with conventional solid dosage forms, alternative approaches have to be developed in order to examine and optimize 3D-printed tablets. Because all of the prepared formulations contained the same ratio of PEGDA and PEG 400, the content of water and PI was constant in all of them and all tablets were fabricated using the same printing parameters, a EZ-LX Compact Table-Top

Testing Machine (Figure 3) was used to measure the penetration force, which reflects the mechanical properties of the tablets, in order to investigate the potential effect of the drug load on the hardness of the fabricated tablets.




Figure 3. Determination of mechanical properties of the tablets on EZ-LX Compact Table-Top Testing Machine.

The results (Table 2) suggest that a higher content of ATH, as well as an increase in the tablet thickness, required a higher force to push the needle probe into the tablet, indicating their influence on the mechanical properties of the fabricated tablets. Taking into consideration that the hardness of the tablets may influence the drug release rate, the impact of those factors were further investigated in the *in vitro* dissolution testing.

Table 2. Measured force in the test with needle probe (mean  $\pm$  SD).

Amount of ATH	Tablet Thickness	Force (N)
5%	1.00	1.49 $\pm$ 0.05
	2.00	2.98 $\pm$ 0.12
	3.00	6.00 $\pm$ 0.17
10%	1.00	1.81 $\pm$ 0.07
	2.00	3.35 $\pm$ 0.22
	3.00	7.40 $\pm$ 0.09
15%	1.00	2.27 $\pm$ 0.01
	2.00	5.58 $\pm$ 0.05
	3.00	11.82 $\pm$ 0.25
20%	1.00	3.26 $\pm$ 0.03
	2.00	7.14 $\pm$ 0.08
	3.00	13.55 $\pm$ 0.30

### 2.4. Dissolution Profiles

Similarly to previously published studies [27,28], printed tablets remained intact after dissolution testing, without signs of erosion or disintegration. Dissolution profiles for all formulations are presented in Figure 4.




Figure 4. Cont.




Figure 4. Dissolution profiles of fabricated tablets containing: (a) 5%; (b) 10%; (c) 15%; and (d) 20% of ATH.

According to Chapter 5.17.1, Recommendation on dissolution testing, in the European Pharmacopoeia Edition 10.2, in terms of the expression of dissolution specification for conventional-release dosage forms, the acceptance criteria at level S1 are that at least 80% of the active substance is released within a specified time, typically 45 min or less. Results of the dissolution testing of fabricated tablets showed that more than 80% of ATH was released in 45 min from 1-mm-thick tablets containing 5%, 10% and 15% of ATH, and from 0.75-mm-thick tablets containing 15% of ATH. To the best of our knowledge, there are no immediate-release dosage forms fabricated by one of the vat polymerization technologies reported so far. In the first study that demonstrated the feasibility of SLA technology in the manufacturing of oral dosage forms, tablets with modified-release characteristics were obtained [21]. Wang et al. demonstrated that a higher content of PEGDA slows down the release rate, due to the higher degree of crosslinking and slower diffusion of the drug from the polymeric matrix. Other attempts to modify and improve the drug release rate include the addition of various excipients, such as water [38], sodium chloride and mannitol [29]. Besides that, the drug release rate can be controlled by changing the geometry of tablets or making a different number of perforations in order to increase the SA/V ratio [27,39,40]. The possibility to fabricate immediate-release dosage forms via DLP 3D technology is very significant because releasing drugs in a timely manner is important for optimal therapeutic effects. Besides that, different clinical conditions require different types of release profiles. There is no comparison in the literature between the standard casting method for the manufacture of immediate-release dosage forms and 3D printing on the efficiency of drug release. However, the advantage of printing is that it is possible to print films or tablets of different thicknesses very precisely and quickly.

Other fabricated tablets expressed modified-release characteristics, with complete release of ATH except from 3-mm-thick tablets containing 15% and 20% of the drug, which released 68.42% and 72.29% of drug, respectively, within 8 h. This slower release rate can be attributed to the longer exposure time during printing which leads to a higher degree of incorporation of the drug within the polymeric matrix and stronger mechanical characteristics of these tablets, as previously shown. The results therefore suggest the influence of geometrical dimensions and mechanical characteristics on drug release profiles.

### 2.5. Differential Scanning Calorimetry (DSC)

DSC (differential scanning calorimetry) analysis of pure ATH and fabricated tablets was performed in order to investigate whether the drug was dispersed or dissolved within the polymeric matrix. The DSC thermogram of raw ATH exhibited a sharp endothermic peak at 169 °C due to melting of drug crystals. There is no sharp melting peak of ATH on

the thermograms of powdered tablets, but broad endotherms between 140 and 160 °C can be observed during heating of formulations containing over 12.5% of ATH (Figure 5). It is difficult to distinguish these endotherms for formulations with a lower content of ATH. Although the absence of drug melting peaks indicates that the drug is dispersed in an amorphous form or dissolved in the polymer, dissolution of drug crystals during heating in DSC analysis cannot be excluded. Therefore, samples were further analyzed by XRPD (X-ray powder diffraction) and polarized light microscopy.




Figure 5. DSC (differential scanning calorimetry) thermograms of: (a) pure ATH prior to printing, and (b) the DLP 3D-printed tablets with different amounts of ATH.

## 2.6. X-ray Powder Diffraction (XRPD)

XRPD was used to study the physical form of the active substance in the fabricated tablets. The X-ray diffractogram of pure ATH exhibited multiple diffraction peaks at  $17.6^\circ$ ,  $18.2^\circ$ ,  $18.9^\circ$ ,  $21.3^\circ$ ,  $23^\circ$ ,  $24.3^\circ$  and  $27.5^\circ$   $2\theta$ , which reflect its crystalline form (Figure 6). Diffraction peaks characteristic for crystalline ATH can be distinguished for formulations containing over 12.5% of the drug. The broadening of ATH peaks in formulations containing below 12.5% of ATH indicates the reduction of drug crystallinity. However, a peak positioned at  $17.6^\circ$   $2\theta$  is present on the diffractograms of formulations with 5%, 7.5% and 10% of ATH, while a peak at  $21.3^\circ$   $2\theta$  can be additionally observed on diffractograms of formulations with 7.5% and 10% of ATH. These results indicate that the drug is present in a crystalline form in all prepared formulations, with a particular reduction in drug crystallinity in formulations containing less than 12.5% of ATH. This is also confirmed with the microscopic observations, which are discussed in the following section.




Figure 6. The X-ray powder diffraction (XRPD) patterns of raw unprocessed ATH and fabricated tablets.

### 2.7. Polarized Light Microscopy

Polarized light microscopy was used for crystal identification as well as for the observation of a cross section of the inner structure of fabricated tablets before and after the performance of dissolution testing.

As shown in Figure 7, crystals are present on the cross section of tablets prepared with different amounts of ATH (5–20%).




Figure 7. Cross section of tablets before dissolution testing containing: (a) 5%; (b) 10%; (c) 15%; (d) 20% of ATH.

This provides additional evidence that ATH remains in tablets after printing in the crystalline state. Another significant observation is the uniform and homogenous distribution of the drug within the polymeric matrix, which further prevents the dose dumping phenomenon in which a relatively large amount of the drug in a controlled-release formulation is quickly released, resulting in a potentially toxic quantity of the drug being introduced into the systemic circulation. This is particularly dangerous in the case of potent drugs, which have a narrow therapeutic index (TI).

It was not possible to observe parallel layers in the printed tablets due to the presence of crystals of drug and the PI which covered them. On the other hand, on the photomicrographs of the cross section of the tablets after dissolution tests, layers are visible in some places, with the generation of cracks and channels which enabled the diffusion of the drug (Figure 8).




Figure 8. Cross section of tablets containing 5% of ATH after dissolution testing.

### 2.8. Fourier-Transform Infrared Spectroscopy (FTIR)

Fourier-transform infrared (FTIR) spectroscopic analysis was used for the assessment of compatibility between the drug and polymers used for the preparation of 3D-printed tablets. The FTIR spectra for PEGDA, PEG 400, ATH powder and fabricated tablets are presented in Figure 9.




Figure 9. Fourier-transform infrared (FTIR) spectra of substances (left) and fabricated tablets (right).

PEG 400 showed characteristic peaks at  $3445\text{ cm}^{-1}$  (O-H stretching),  $2866\text{ cm}^{-1}$  (C-H stretching) and  $1096\text{ cm}^{-1}$  (C-O-C ether stretching) [41]. Peaks at  $2866\text{ cm}^{-1}$  and  $1096\text{ cm}^{-1}$  are also present in the spectra of the printed tablets. The spectrum of uncured PEGDA had characteristic peaks at  $2866\text{ cm}^{-1}$  (CH<sub>3</sub> stretching),  $1721\text{ cm}^{-1}$  (C=O stretching) and  $1636\text{ cm}^{-1}$  (acrylate C=C stretching) [27,42]. After the photopolymerization process, it was not possible to identify the acrylate-related peaks at  $1636\text{ cm}^{-1}$ , due to the conversion of C=C to C-C bonds [41]. The major peaks identified in the pure ATH spectra were clearly observed in the spectra of all fabricated tablets, which indicates the absence of interactions between drug and polymers.

### 2.9. ANN Modeling

Data from 23 experiments were trained with the Kohonen learning rule in self-organizing maps (SOMs) with learning rate of 0.5. After training, SOMs are presented in Figure 10. Each input and output is presented as a separate region (map). The map consists of hexagonal cells, where each cell represents the SOM node. The node is associated with a data point to which it is closest.

Data points (experimental runs) that are used for SOM training are presented as black dots in a map. Distribution of data through the region can be easily visualized on the maps, while the color scale of a variable gives us information about data clustering. For example, the black dot on the right top corner of the maps is the experimental run with the lowest



percent of ATH (blue cluster), with tablet thickness of 0.75. For that experimental run, the drug release after 15 min was the fastest (red cluster in the top right corner of the map corresponding to drug release after 15 min).

The next step in modeling was developing ANNs that could describe influence of tablet thickness and drug loading on ATH release from printed tablets. A total of 23 experimental runs were divided into training set (17), validation (4) and test set (2). A generalized regression neural network (GRNN) was trained (Figure 11). GRNNs have exactly four layers: input, a layer of radial centers, a layer of regression units, and output. The radial layer units represent the centers of clusters of known training data. This layer was trained by a K-means clustering algorithm, using smoothing factor 0.02. The maximal number of neurons in this layer is equal to number of training cases. During training, the number of units in the second layer was varied, and the lowest root mean square (RMS) for the training and validation data set was obtained with 17 units in the second layer. The third regression layer has one more unit then the output layer (7). The regression and output layer are trained extremely quickly using the specialized algorithm provided (called a division algorithm).




Figure 10. Self-organizing maps of drug release data; black dots represent properties of the same nodes.




Figure 11. Schematic representation of the used GRNN (generalized regression neural network).

After training, values for RMS error were 0.126 for the training set, 0.040 for the validation set and 0.035 for the testing set.

Response surfaces predicted by GRNN, representing outputs (Y1–Y6 percent of drug released after predetermined time intervals) as a function of tablet thickness and drug loading, are presented in Figure 12a–f. These response surfaces clearly show GRNN predictions of drug release, as a function of tablet thickness and drug loading.




Figure 12. Cont.





Figure 12. Cont.



**Figure 12.** Response surfaces, representing outputs (Y1–Y6 percent of drug released after pre-determined time intervals) as a function of drug loading (% ATH) and tablet thickness: (a) Y1—after 15 minutes; (b) Y2—after 30 minutes; (c) Y3—after 60 minutes; (d) Y4—after 120 minutes; (e) Y5—after 240 minutes; (f) Y6—after 360 minutes.

Additionally, for two test formulations, experimentally observed dissolution profiles versus profiles predicted using trained networks were evaluated using similarity factor  $f_2$ . Dissolution profiles (experimentally observed vs. predicted) for T1 and T2 formulation are presented in Figure 13. Predicted dissolution profiles are similar to experimentally observed profiles, with calculated similarity factors of 51.05 and 70.13, respectively.

These results demonstrated the ability of a trained GRNN to predict ATH dissolution profiles within a defined design space of tablet thickness between 0.75 and 3.00 mm and drug loading between 5% and 20%.

Additionally, within this design space, by the appropriate choice of tablet thickness and drug content, it is possible to achieve either immediate or prolonged release of ATH, using the same formulation and printing process.




Figure 13. Experimentally observed versus GRNN-predicted dissolution profiles of ATH from formulations (a) T1 and (b) T2.

### 3. Materials and Methods

#### 3.1. Materials

PEGDA, average MW 700, was obtained from Sigma-Aldrich, Tokyo, Japan. PEG 400, average MW 400, was purchased from Fagron B.V., Rotterdam, The Netherlands. ATH was kindly provided by Hemofarm AD, Vrsac, Serbia. DPPO was purchased from Sigma-Aldrich, Steinheim, Germany. All other chemicals used in the study were of analytical grade.

### 3.2. Methods

#### 3.2.1. Preparation of Photoreactive Mixtures

In this study, ATH was used as a model substance, PEGDA as the photopolymerizable monomer, DPPO as a photoinitiator and PEG 400 as an excipient which enhances incomplete drug release from tablets obtained by vat photopolymerization techniques.

Content of ATH varied from 5.00% to 20.00% (*w/w*), while a 3:1 ratio of PEGDA/PEG 400 was the same in all formulations in order to obtain tablets with appropriate mechanical and release properties, based on a previously published study [30]. All formulations contained 10% water and 0.10% DPPO. Compositions of the formulations are given in Table 3.

Table 3. Compositions (*w/w*) of photoreactive mixtures used for 3D printing.

Formulation	ATH	PEGDA	PEG 400	Water	DPPO
D5	5.00	63.70	21.20	10.00	0.10
D7.5	7.50	61.80	20.60	10.00	0.10
D10	10.00	59.93	19.97	10.00	0.10
D12.5	12.50	58.05	19.35	10.00	0.10
D15	15.00	56.18	18.72	10.00	0.10
D20	20.00	52.43	17.47	10.00	0.10

A total of 50 g of each formulation was prepared by mixing with the magnetic stirrer for 12 h until complete dissolution, keeping the mixture protected from light. The mixture was then transferred into the resin tray and printing was initiated.

#### 3.2.2. 3D Printing of Dosage Forms

A cylindrical 3D model of the printed tablets was designed with Autodesk Fusion 360 software version 2.0.8809 (Autodesk Inc, San Rafael, CA, USA) and was exported as a stereolithography file (.stl) into the 3D printer software (Chitubox, version 1.7.0). All tablets were printed with Wanhao Duplicator 8 printer (Wanhao, Zhejiang, China). The diameter of all tablets was the same (8 mm) but their thickness was varied in the way shown in Table 4.

Table 4. Dimensions (diameter and thickness) of created 3D models.

Formulation	Thickness (mm)	Diameter (mm)
D5	1.00, 1.25, 1.50, 1.75, 2.00, 3.00	8.00
D7.5	2.50	8.00
D10	1.00, 1.25, 1.50, 2.00, 3.00	8.00
D12.5	1.50	8.00
D15	0.75, 1.00, 1.50, 2.00, 3.00	8.00
D20	0.75, 1.00, 1.50, 2.00, 3.00	8.00

In order to optimize the printing process, preliminary experiments were conducted to establish printing parameters which will enable rapid and successful printing. In accordance with the results of these experiments, all tablets were printed with the same parameters shown in Table 5.

#### 3.2.3. Mass and Dimension Variation

3D-printed tablets were washed with 2-propanol and wiped up with filter paper immediately after printing, to remove any excess uncured formulation on the surface of the tablets. Tablets were then weighed on an analytical balance (Kern & Sohn, Germany) and measured (diameter and thickness) using a digital caliper (Vogel Germany GmbH & Co. KG, Kevelaer, Germany). Measurements were performed on 10 tablets for each formulation.

Table 5. Parameters of printing process.

Parameter	Value
Layer height	0.1 mm
Bottom layers	5
Exposure time	20 s
Bottom exposure time	30 s
Bottom lift distance	5 mm
Lifting distance	5 mm
Bottom lift speed	300 mm/min
Lifting speed	300 mm/min
Retract speed	300 mm/min

### 3.2.4. Mechanical Properties of 3DP Tablets

It was not possible to perform a conventional hardness test as the tester could not break some of the fabricated tablets, particularly the thinnest one, due to their movement and deformation into the tester machine. Furthermore, because of the smoothness and elasticity of fabricated tablets, the results of a conventional friability test would not provide any significant information. An alternative approach, based on the measurement of the force required to push a needle probe into a tablet to a particular depth, was used to determine the effect of the drug load on mechanical characteristics of tablets. Testing was performed on an EZ-LX Compact Table-Top Testing Machine (Shimadzu, Japan). The test was performed on 1-mm-, 2-mm- and 3-mm-thick tablets, for which the penetration depth was set at 0.5 mm, 1 mm and 2 mm, respectively. The speed of the needle probe was 2 mm/min and three tablets of each formulation were examined.

### 3.2.5. Determination of Drug Content in 3DP Tablets

The drug content in 3D-printed tablets was determined by UV/VIS spectrophotometry (Evolution 300, Thermo Fisher Scientific, Waltham, MA, USA) at the wavelength of 270 nm [43]. For standard preparation, 10 mg of ATH was dissolved in 100 mL of distilled water, shaken in an ultrasonic bath Bandelin-Sonorex RK102H (Sonorex-Bandelin, Berlin, Germany) for 15 min at room temperature, cooled and then filtered through 0.45 µm filters (Millipore, Bedford, MA, USA). For test preparation, three tablets of each formulation were crushed using a mortar and pestle. The mass of each tablet equivalent to 10 mg of ATH was weighed and dissolved in a volumetric flask with 100 mL of distilled water and shaken in an ultrasonic bath for 15 min. Samples then underwent the same procedure as described for standard preparation.

### 3.2.6. In Vitro Drug Release Testing

Drug dissolution profiles of the printed tablets were obtained by USP II Erweka DT 600 (Erweka, Langen, Germany) apparatus. Tablets were placed in 500 mL of distilled water for 8 h. The paddle speed was fixed at 50 rpm, and the testing was conducted at  $37 \pm 0.5$  °C. Samples (5 mL) were withdrawn at 15, 30, 45, 60, 120, 180, 240, 300, 360, 420 and 480 min time intervals, filtered through 0.45 µm filters (Millipore, Bedford, MA, USA) and the amount of released ATH was determined UV spectrophotometrically at 270 nm (Evolution 300, Thermo Fisher Scientific, Waltham, MA, USA). According to Krkobabic et al., the type of apparatus (paddle apparatus or flow-through cell) and medium (distilled water or 0.1 M HCl) do not significantly affect the ATH dissolution rate from 3D-printed tablets [30].

### 3.2.7. Differential Scanning Calorimetry (DSC)

DSC was performed on a DSC 1 instrument (Mettler Toledo, Giessen, Germany). Precisely weighed 5–10 mg of pure ATH and powdered tablets were placed in pierced aluminum pans and subjected to heating at 10 °C/min in the range from 25 to 200 °C under constant nitrogen gas flow of 50 mL/min. An empty aluminum pan was used as a

reference. The obtained data were further analyzed in the STARe software (version 12.10, Mettler, Toledo).

### 3.2.8. X-ray Powder Diffraction (XRPD)

XRPD measurements were done on a Philips PW 1050 powder diffractometer at room temperature with Ni-filtered Cu K $\alpha$  1,2 radiation, scintillation detector and Bragg–Brentano focusing geometry. The intensity and voltage applied were 40 kV and 30 mA. The XRPD patterns were taken within the angular range of 5–40° 2 $\theta$  in steps of 0.05° and scanning time of 4 s per step.

### 3.2.9. Polarized Light Microscopy

An Olympus BX53-P polarized microscope (Olympus, Tokyo, Japan) with UPLFLN4XP and UPLFLN10XP objectives was used for visual examination of a cross section of the tablets' internal structure before and after dissolution testing, as well as for crystal detection. Photos were acquired using cellSens Entry Version 1.14 software (Olympus, Tokyo, Japan).

### 3.2.10. Fourier-Transform Infrared Spectroscopy (FTIR)

Interactions between the drug and polymers were assessed using FTIR spectroscopy. Spectroscopic analyses of raw materials and crushed tablets were performed using a Nicolet iS10 (Thermo Scientific, Waltham, MA, USA) FTIR spectrometer, equipped with a single reflection ATR system (Smart iTR, Thermo Scientific, Waltham, MA, USA) with diamond plate and ZnSe lens. The spectra were collected in the frequency range from 4000 to 650 cm<sup>-1</sup>, with the resolution of 2 cm<sup>-1</sup>.

## 3.3. ANN Modeling

For ANN modeling, two types of neural networks were used. Firstly, a self-organizing map (SOM), as an unsupervised artificial neural network, was used in order to help us to visualize the influence of inputs (tablet thickness and drug loading) on ATH release from printed tables. Peltarion® software (Synapse, Sweden) was applied for SOM development and visualization.

Secondly, a generalized regression neural network (GRNN) was used for model development that could predict drug release from printed tablets. This network was built using TIBCO Statistica® Software 13.5.0 (StatSoft Inc).

For both networks, input variables were: X1, tablet thickness (from 0.75–3.00 mm) and X2, ATH loading (from 5% to 20%). Dependent variables (outputs) were: percent of drug release after 15 min (Y1), 30 min (Y2), 60 min (Y3), 120 min (Y4), 240 min (Y5) and 360 min (Y6).

Data from 23 experimental runs were divided in training, validation and test sets (17:4:2). The best network was chosen based on the least RMS values for training, validation and test data set.

## 4. Conclusions

In this study, the possibility of successful fabrication of tablets with immediate- and modified-release characteristics containing different drug loadings with DLP 3D printing has been demonstrated. This further emphasizes the potential of this technology in the production of more acceptable dosage forms containing doses that are adjusted to the patient's characteristics, which is particularly important for pediatric and geriatric populations, resulting in favorable therapy outcomes and adherence, and reduction of adverse effects and drugs toxicity.

**Author Contributions:** Conceptualization, G.S., D.M., I.A., N.P., J.K. and S.I.; methodology, G.S., D.M. and S.I.; software, G.S. and S.I.; validation, G.S., D.M. and S.I.; formal analysis, G.S., D.M., I.A. and S.I.; investigation, G.S.; resources, J.K. and S.I.; data curation, G.S. and S.I.; writing—original draft preparation, G.S. and S.I.; writing—review and editing, G.S., D.M., I.A., N.P., J.K. and S.I.;



visualization, G.S., D.M. and S.I.; supervision, S.I.; project administration, S.I. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Ministry of Education, Science and Technological development, Republic of Serbia, project no: 451-03-68/2020-14/200161.

**Acknowledgments:** Authors would like to thank Branka Ivković, associate professor from the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade for FT-IR analysis.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds are not available from the authors.

## References

- Goole, J.; Amighi, K. 3D printing in pharmaceuticals: A new tool for designing customized drug delivery systems. *Int. J. Pharm.* **2016**, *499*, 376–394. [CrossRef] [PubMed]
- Apricia Pharmaceuticals, the Future of Pharmaceutical Manufacturing. Available online: <https://www.aprecia.com/technology/zipdose> (accessed on 20 November 2020).
- Awad, A.; Trenfield, S.J.; Gaisford, S.; Basit, A.W. 3D printed medicines: A new branch of digital healthcare. *Int. J. Pharm.* **2018**, *548*, 586–596. [CrossRef] [PubMed]
- Trenfield, S.J.; Awad, A.; Goyanes, A.; Gaisford, S.; Basit, A.W. 3D Printing Pharmaceuticals: Drug Development to Frontline Care. *Trends Pharmacol. Sci.* **2018**, *39*, 440–451. [CrossRef]
- Redekop, W.K.; Mladsi, D. The Faces of Personalized Medicine: A Framework for Understanding Its Meaning and Scope. *Value Health* **2013**, *16*, S4–S9. [CrossRef] [PubMed]
- Okwuosa, T.C.; Pereira, B.C.; Arafat, B.; Cieszynska, M.; Isreb, A.; Alhnan, M.A. Fabricating a shell-core delayed release tablet using dual FDM 3D printing for patient-centred therapy. *Pharm. Res.* **2017**, *34*, 427–437. [CrossRef] [PubMed]
- Zemq, L.; Melocchi, A.; Maroni, A.; Gazzaniga, A. Three-dimensional printing of medicinal products and the challenge of personalized therapy. *J. Pharm. Sci.* **2017**, *106*, 1697–1705. [CrossRef] [PubMed]
- Alhnan, M.A.; Okwuosa, T.C.; Sadia, M.; Wan, K.W.; Ahmed, W.; Arafat, B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. *Pharm. Res.* **2016**, *33*, 1817–1832. [CrossRef]
- Alomari, M.; Mohamed, F.H.; Basit, A.W.; Gaisford, S. Personalised dosing: Printing a dose of one's own medicine. *Int. J. Pharm.* **2015**, *494*, 568–577. [CrossRef]
- Norman, J.; Madurawe, R.D.; Moore, C.M.V.; Khan, M.A.; Khairuzzaman, A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv. Drug. Deliv. Rev.* **2017**, *108*, 39–50. [CrossRef]
- Sun, Y.; Soh, S. Printing tablets with fully customizable release profiles for personalized medicine. *Adv. Mater.* **2015**, *27*, 7847–7853. [CrossRef]
- Khaled, S.A.; Burley, J.C.; Alexander, M.R.; Yang, J.; Roberts, C.J. 3D printing of tablets containing multiple drugs with defined release profiles. *Int. J. Pharm.* **2015**, *494*, 643–650. [CrossRef] [PubMed]
- Awad, A.; Fina, F.; Trenfield, S.J.; Patel, P.; Goyanes, A.; Gaisford, S.; Basit, A.W. 3D Printed Pellets (Miniprintlets): A Novel, Multi-Drug, Controlled Release Platform Technology. *Pharmaceutics* **2019**, *11*, 148. [CrossRef] [PubMed]
- Robles-Martinez, P.; Xu, X.; Trenfield, S.J.; Awad, A.; Goyanes, A.; Telford, R.; Basit, A.W.; Gaisford, S. 3D printing of a multi-layered polypill containing six drugs using a novel stereolithographic method. *Pharmaceutics* **2019**, *11*, 274. [CrossRef] [PubMed]
- Zhang, J.; Feng, X.; Patil, H.; Tiwari, R.V.; Repka, M.A. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. *Int. J. Pharm.* **2017**, *519*, 186–197. [CrossRef]
- Solanki, N.G.; Tahsin, M.; Shah, A.V.; Serajuddin, A.T.M. Formulation of 3D printed tablet for rapid drug release by fused deposition modeling: Screening polymers for drug release, drug-polymer miscibility and printability. *J. Pharm. Sci.* **2018**, *107*, 390–401. [CrossRef]
- Fina, F.; Madla, C.M.; Goyanes, A.; Zhang, J.; Gaisford, S.; Basit, A.W. Fabricating 3D printed orally disintegrating printlets using selective laser sintering. *Int. J. Pharm.* **2018**, *541*, 101–107. [CrossRef]
- Fina, F.; Goyanes, A.; Gaisford, S.; Basit, A.W. Selective laser sintering (SLS) 3D printing of medicines. *Int. J. Pharm.* **2017**, *529*, 285–293. [CrossRef]
- Zheng, X.; Deotte, J.; Alonso, M.P.; Farquar, G.R.; Weisgraber, T.H.; Gemberling, S.; Lee, H.; Fang, N.; Spadaccini, C.M. Design and optimization of a light-emitting diode projection micro-stereolithography three-dimensional manufacturing system. *Rev. Sci. Instrum.* **2012**, *83*, 125001. [CrossRef]
- Patel, D.K.; Sakhaei, A.H.; Layani, M.; Zhang, B.; Ge, Q.; Magdassi, S. Highly Stretchable and UV Curable Elastomers for Digital Light Processing Based 3D Printing. *Adv. Mater.* **2017**, *29*, 1–7. [CrossRef]
- Wang, J.; Goyanes, A.; Gaisford, S.; Basit, A.W. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. *Int. J. Pharm.* **2016**, *503*, 207–212. [CrossRef]

22. Kim, S.Y.; Shin, Y.S.; Jung, H.D.; Hwang, C.J.; Baik, H.S.; Cha, J.Y. Precision and trueness of dental models manufactured with different 3-dimensional printing techniques. *Am. J. Orthod. Dentofac. Orthop.* **2018**, *153*, 144–153. [CrossRef] [PubMed]
23. Lim, S.H.; Ng, J.Y.; Kang, L. Three-dimensional printing of a microneedle array on personalized curved surfaces for dual-pronged treatment of trigger finger. *Biofabrication* **2017**, *9*, 015010. [CrossRef] [PubMed]
24. Yao, W.; Li, D.; Zhao, Y.; Zhan, Z.; Jin, G.; Liang, H.; Yang, R. 3D Printed Multi-Functional Hydrogel Microneedles Based on High-Precision Digital Light Processing. *Micromachines* **2020**, *11*, 17. [CrossRef] [PubMed]
25. Sun, Y.; Ruan, X.; Li, H.; Kathuria, H.; Du, G.; Kang, L. Fabrication of non-dissolving analgesic suppositories using 3D printed moulds. *Int. J. Pharm.* **2016**, *513*, 717–724. [CrossRef]
26. Yang, Y.; Zhou, Y.; Lin, X.; Yang, Q.; Yang, G. Printability of External and Internal Structures Based on Digital Light Processing 3D Printing Technique. *Pharmaceutics* **2020**, *12*, 207. [CrossRef]
27. Kadry, H.; Wadnap, S.; Xu, C.; Ahsan, F. Digital light processing (DLP) 3D-printing technology and photoreactive polymers in fabrication of modified-release tablets. *Eur. J. Pharm. Sci.* **2019**, *135*, 60–67. [CrossRef]
28. Madzarevic, M.; Medarevic, D.; Vulovic, A.; Sustersic, T.; Djuris, J.; Filipovic, N.; Ibric, S. Optimization and Prediction of Ibuprofen Release from 3D DLP Printlets Using Artificial Neural Networks. *Pharmaceutics* **2019**, *11*, 544. [CrossRef]
29. Krkobabić, M.; Medarević, D.; Cvijić, S.; Grujić, B.; Ibrić, S. Hydrophilic excipients in digital light processing (DLP) printing of sustained release tablets: Impact on internal structure and drug dissolution rate. *Int. J. Pharm.* **2019**, *572*, 118790. [CrossRef]
30. Krkobabić, M.; Medarević, D.; Pešić, N.; Vasiljević, D.; Ivković, B.; Ibrić, S. Digital Light Processing (DLP) 3D Printing of Atomoxetine Hydrochloride Tablets Using Photoreactive Suspensions. *Pharmaceutics* **2020**, *12*, 833. [CrossRef]
31. Larush, L.; Kaner, I.; Fluksman, A.; Tamsut, A.; Pawar, A.A.; Lesnovski, P.; Berny, O.; Magdassi, S. 3D printing of responsive hydrogels for drug-delivery systems. *J. 3D Print. Med.* **2017**, *1*, 219–229. [CrossRef]
32. Ibrić, S.; Djuriš, J.; Parojić, J.; Djurić, Z. Artificial neural networks in evaluation and optimization of modified release solid dosage forms. *Pharmaceutics* **2012**, *4*, 531–550. [CrossRef] [PubMed]
33. Sweetman, S.C. *Martindale*, 36th ed.; Pharmaceutical Press: London, UK, 2009; p. 2151.
34. Pelras, T.; Glass, S.; Scherzer, T.; Elsner, C.; Schulze, A.; Abel, B. Transparent low molecular weight poly(ethylene glycol) diacrylate-based hydrogels as film media for photoswitchable drugs. *Polymers (Basel)* **2017**, *9*, 639. [CrossRef]
35. Fernández-García, R.; Prada, M.; Bolás-Fernández, F.; Ballesteros, M.P.; Serrano, D.R. Oral fixed-dose combination pharmaceutical products: Industrial manufacturing versus personalized 3D printing. *Pharm. Res.* **2020**, *37*, 132. [CrossRef] [PubMed]
36. Medicines & Healthcare Products Regulatory Agency (MHRA). MHRA Products. Available online: <https://products.mhra.gov.uk/> (accessed on 4 December 2020).
37. Brackert, L.; McDonough, E.; Ashleigh, S.; Wilson, F.; Shakeshaft, J.; Ohia, U.; Mistry, P.; Jones, H.; Kanji, N.; Liu, F.; et al. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)). *BMJ Open.* **2020**, *10*, e036508. [CrossRef] [PubMed]
38. Martínez, P.R.; Goyanes, A.; Basit, A.W.; Gaisford, S. Fabrication of drug-loaded hydrogels with stereolithographic 3D printing. *Int. J. Pharm.* **2017**, *532*, 313–317. [CrossRef] [PubMed]
39. Healy, A.V.; Fuertmayor, E.; Doran, P.; Geever, L.M.; Higginbotham, C.L.; Lyons, J.G. Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography. *Pharmaceutics* **2019**, *11*, 645. [CrossRef]
40. Karakurt, I.; Aydogdu, A.; Çikrikci, S.; Orozco, J.; Lin, L. Stereolithography (SLA) 3D printing of ascorbic acid loaded hydrogels: A controlled release study. *Int. J. Pharm.* **2020**, *584*, 119428. [CrossRef]
41. Banerjee, A.; Blasiak, B.; Pasquier, E.; Tomanek, B.; Trudel, S. Synthesis, characterization, and evaluation of PEGylated first-row transition metal ferrite nanoparticles as T2 contrast agents for high-field MRI. *RSC Adv.* **2017**, *7*, 38125–38134. [CrossRef]
42. Clark, E.A.; Alexander, M.R.; Irvine, D.J.; Roberts, C.J.; Wallace, M.J.; Sharpe, S.; Yoo, J.; Hague, R.J.M.; Tuck, C.J.; Wildman, R.D. 3D printing of tablets using inkjet with UV photoinitiation. *Int. J. Pharm.* **2017**, *529*, 523–530. [CrossRef]
43. Bhitre, M.J.; Bhanage, B.; Shirgaonkar, S.J.; Pawar, A.S. Formulation and evaluation of elementary osmotic pump tablet of atomoxetine hydrochloride. *Int. J. Pharm. Bio. Sci.* **2013**, *3*, 118–134.

# Molecules

*Molecules* is the leading international, peer-reviewed, open access journal of chemistry. *Molecules* is published semimonthly online by MDPI. The International Society of Nucleosides, Nucleotides & Nucleic Acids (IS3NA), the Spanish Society of Medicinal Chemistry (SEQT) and the International Society of Heterocyclic Chemistry (ISHC) are affiliated with *Molecules* and their members receive a discount on the article processing charges.

- **Open Access** — free for readers, with article processing charges (APC) paid by authors or their institutions
- **High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, Embase, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.
- **Journal Rank:** JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))
- **Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 13.4 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2022).
- **Recognition of Reviewers:** reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- **Sections:** published in 26 topical sections.
- **Testimonials:** See what our editors and authors say about *Molecules*.
- **Companion journals for *Molecules* include: *Foundations* and *Photochem*.**

Home / Molecules




## Journal Menu

- [Molecules Home](#)
- [Aims & Scope](#)
- [Editorial Board](#)
- [Reviewer Board](#)
- [Topical Advisory Panel](#)
- [Instructions for Authors](#)



## Molecules

*Molecules* is the leading international, peer-reviewed, open access journal of chemistry. *Molecules* is published semimonthly online by MDPI. The International Society of Nucleosides, Nucleotides & Nucleic Acids (IS3NA), the Spanish Society of Medicinal Chemistry (SEQT) and the International Society of Heterocyclic Chemistry (ISHC) are affiliated with *Molecules* and their members receive a discount on the article processing charges.



## E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal

## News

28 June 2023  
2022 Impact Factors for MDPI Journals

15 June 2023  
**Molecules** Receives an Increased CiteScore of 6.7

## **Gordana Boljević - biografija**

Gordana Boljević (udata Stanojević) je rođena 27.11.1989. godine u Podgorici, gdje je završila osnovnu školu i gimnaziju kao dobitnik diplome Luča I. Farmaceutski fakultet u Podgorici upisala je 2008. godine i diplomirala u roku sa prosječnom ocjenom 9,99. U toku studija bila je dobitnik više nagrada i stipendija, među kojima treba izdvojiti Studentsku nagradu glavnog grada Podgorice za najbolje studente 2010. godine, stipendiju Ministarstva prosvjete i nauke za talentovane studente...

Nakon obavljenog pripravničkog staža zasniva radni odnos u apoteci, a od 2015. godine zaposlena je u Institutu za lijekove i medicinska sredstva, trenutno na poziciji rukovoditeljke Centra za odobravanje lijekova.

Od 2013. godine angažovana je kao saradnica u nastavi na Medicinskom fakultetu u Podgorici, na studijskom programu Farmacija, gdje učestvuje u izvođenju praktične nastave na predmetima Farmaceutska tehnologija I, II i III.

## Gordana Boljević - bibliografija

- **Stanojević, G.**; Medarević, D.; Adamov, I.; Pešić, N.; Kovačević, J.; Ibrić, S. Tailoring Atomoxetine Release Rate from DLP 3D-Printed Tablets Using Artificial Neural Networks: Influence of Tablet Thickness and Drug Loading. *Molecules* 2021, 26, 111
- Adamov, I.; **Stanojević, G.**; Medarević, D.; Ivković, B.; Kočović, D.; Mirković, D.; Ibrić, S.. Formulation and characterization of immediate-release oral dosage forms with zolpidem tartrate fabricated by digital light processing (DLP) 3D printing technique. *International Journal of Pharmaceutics* 2022, 624, 122046
- **G. Boljević**, M. Madžarević, I. Adamov, Z. Potpara, S. Ibrić: The effect of the tablets thickness and the type of photoinitiator on atomoxetine dissolution rate from SLA 3DP tablets. Poster Presentation at the 8th BBBB International Conference on Pharmaceutical Sciences, Cesme, Izmir, Turkey, October 2019.
- M. Krkobabić, Đ. Medarević, **G. Boljević**, Lj. Solomun, S. Ibrić: Mannitol's role in forming pores in printlets produced by stereolithography. Oral research presentation at the Third Congress of Pharmacists of Montenegro, Budva, Montenegro, May 2019.
- M. Rolevski, B. Kučević, **G. Boljević**, S. Mugoša and M. Mikov: Potentially inappropriate medication use in the elderly in Montenegro. Poster presentation at the 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR), Vienna, Austria, September 2012



**Univerzitet Crne Gore**  
adresa / address\_ Cetinjska br. 2  
81000 Podgorica, Crna Gora  
telefon / phone\_ 00382 20 111 255  
fax\_ 00382 20 114 230  
mail\_rektorat@ucg.me  
web\_www.ucg.ac.me  
**University of Montenegro**

Broj / Ref 03 - 1332  
Datum / Date 19 04. 20 19

Na osnovu člana 72 stav 2 Zakona o visokom obrazovanju („Službeni list Crne Gore“ br. 44/14, 47/15,40/16,42/17,71/17 55/18 i 3/19) i člana 32 stav 1 tačka 9 Statuta Univerziteta Crne Gore, Senat Univerziteta Crne Gore, na sjednici održanoj 19. aprila 2019.godine, donio je

## **ODLUKU O IZBORU U ZVANJE**

Dr ZORICA POTPARA bira se u akademsko zvanje vanredni profesor Univerziteta Crne Gore za oblasti: Socijalna farmacija i Farmaceutska tehnologija i kozmetologija (Osnovi industrijske farmacije, Osnovi farmaceutskog menadžmenta, Farmaceutska etika i zakonodavstvo i Uvod u farmaciju, na studijskom programu Farmacija) na Medicinskom fakultetu Univerziteta Crne Gore, na period od pet godina.

**SENAT UNIVERZITETA CRNE GORE  
PREDSJEDNIK**

**Prof.dr Danilo Nikolić, rektor**

## BIOGRAFIJA ZORICA POTPARA

Rodena sam 08.01.1963.god. u Nikšiću. Crna Gora. Osnovnu školu završila sam u Nikšiću kao nosilac diplome Luča I. Gimnaziju, smjer biohemija i molekularna biologija, završila sam 1981.god. u Beogradu kao nosilac Vukove diplome.

Školske 1981/82.godine upisala sam Farmaceutski fakultet Univerziteta u Beogradu, a diplomirala na istom u novembru 1985.god.

Školske 1988/89.godine upisala sam zdravstvenu specijalizaciju iz farmaceutske tehnologije na Farmaceutskom fakultetu u Beogradu, u trajanju od tri godine. Specijalizacija je bila raspisana za potrebe proizvodnje Galenske laboratorije pri AU "Montefarm". Specijalistički ispit sa temom "Tablete Paracetamola á 500mg" (mentor prof.dr Milica Jovanović, prof.dr Zorica Đurić). Odbranila sam u novembru 1991.godine, stekavši naziv specijalista farmaceutske tehnologije. Rezultati istraživanja su iskorišteni za izradu formulacije tableta Paracetamola, koje su se izradivale kao galenski preparat.

2007.god. upisala sam doktorske studije na Medicinskom fakultetu u Kragujevcu, smjer Eksperimentalna i klinička farmakologija. Doktorsku disertaciju "Ispitivanje biološke aktivnosti preparata peloida sa lokaliteta ulcinjske obale Jadranskog mora", pod mentorstvom prof.dr Slobodana Jankovića, odbranila sam u decembru 2011.god. na Medicinskom fakultetu u Kragujevcu i stekla akademsko zvanje doktora medicinskih nauka. Eksperimentalni dio teze je raden u PZU "Fontis", koji je obuhvatio ispitivanja dejstva dermokožmetičkog preparata za akne i njegu kože, sa prirodnim resursom-morskim peloidom sa područja ulcinjske Solane. Rezultati ispitivanja su potvrđeni kroz dugogodišnju primjenu preparata, sa odličnim ishodima.

Obavezni pripravnički staž za farmaceute obavila sam u apoteci „Zemun“ u Zemunu, opština Beograd, 1986.god. a nakon toga položila državni ispit.

1987.god. počinjem da radim u apoteci „Podgorica“ u Podgorici u okviru Apotekarske Ustanove Crne Gore.

1988.godine prelazim u novootvorenu galensku laboratoriju i iste godine zbog potreba proizvodnje upisujem specijalizaciju iz farmaceutske tehnologije u Beogradu gdje provodim naredne tri godine.

Po povratku u Podgoricu, nastavila sam sa radom u galenskoj laboratoriji gdje se proizvodilo više od 40 galenskih pripravaka. Za potrebe proizvodnje sirupa, boravila sam u fabrici ljekova "Galenika" u Beogradu, gdje sam radila transfer iz laboratorijske u serijsku proizvodnju, zbog potreba tržišta Crne Gore.

Kao specijalista farmaceutske tehnologije, učestvovala sam u izradi mnogih formulacija galenskih preparata, koji su distribuirani na teritoriji Crne Gore.

Od 1997. do 2001.god. radila sam u ICN-u Crna Gora, gdje sam bila rukovodilac pogona za izradu Flonivina BS.

2001.god. sam na mjestu direktora proizvodnje u novootvorenoj fabrici čvrstih oblika „Habitpharm“, u Podgorici.

2002. godine fabricu preuzima „Hemomont“ i kao rukovodilac čvrstih formi radim na transferu tehnologije čvrstih farmaceutskih oblika iz fabrike „Hemofarm“ Vršac.

2003.godine prelazim u privatnu dermatovenerološku ordinaciju „Fontis“, koja u svom sastavu ima proizvodnju dermokožmetičkih preparata za njegu zdrave i liječenje problematične kože. Radim na kreiranju novih preparata kao rukovodilac proizvodnje.

Aktivno sam učestvovala u pripremi elaborata za otvaranje Samostalnog studijskog programa Farmacije u Podgorici, koji je otvoren 2007.god. a 2010.god transformisan u Farmaceutski fakultet. Tokom ovog perioda bila sam saradnik na predmetima:

Farmaceutska tehnologija I, Farmaceutska tehnologija II,

Farmaceutska tehnologija III, Industrijska farmacija i koordinator za stručnu praksu.

Odlukom Senata br.08-2713 od 19.12. 2013. izabrana sam u zvanje docenta na Univerzitetu Crne Gore, a potom zasnovala radni odnos na Farmaceutskom fakultetu, danas studijskom programu Farmacija na Medicinskom fakultetu.

Bila sam član Strukovnog vijeća za prirodne i tehničke nauke, član Senata Univerziteta Crne Gore, dekan Farmaceutskog fakulteta ( jun-septembar 2015.godine), do integracije sa Medicinskim fakultetom.

17.03.2016.godine imenovana sam za rukovodioca studijskog programa Farmacija na Medicinskom fakultetu u Podgorici. Prvi sam farmaceut doktor nauka u Crnoj Gori i prvi farmaceut-nastavnik na Farmaceutskom fakultetu u Podgorici, danas studijskom programu Farmacija.



## PREGLED RADOVA

### I -Radovi objavljeni u časopisima koji se nalaze u međunarodnim bazama podataka

- Zorica Potpara, Snezana Pantovic, Natasa Duborija-Kovacevic, Vanja Tadic, Tanja Vojinovic and Nada Marstijepovic. *The Properties of the Ulcinj Peloid make it Unique Biochemical Laboratory Required for the Treatment of Problematic Skin and Health Care. Natural Product Communications*. 2017; 12(6) :p911-14. ISSN 1934-578X (printed); ISSN 1555-9475 (online)
- Tanja Vojinović, Djordje Medarević, Edina Vranić, Zorica Potpara, Marko Krstić, Jelena Djuriš, Svetlana Brić. *Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine. Saudi Pharmaceutical Journal*. 2018 ; 26(5); p 725-32. ISSN:1319 -0164
- Zorica Potpara, Nataša Duborija-Kovačević. *Effects of the peloid cream from the Montenegrin Adriatic coast on skin humidity, transepidermal water loss and erythema index, examined with skin bioengineering in vivo methods*. *Farmacia* 2012; Vol.60(4): str.524-34
- Slobodan Janković, Dragica Bojović, Dubravka Vukadinović, Elmedina Daglar, Marija Janković, Dragomir Laudanović, Vladan Lukić, Vesna Mišković, Zorica Potpara, Ivana Projović, Vesna Čokanović, Nadežda Petrović, Marko Folić, Viktorija Savić. *Faktori rizika od nastanka rekurentne vulvovaginalne kandidijaze*. *Vojnosanitetski pregled* 2010. Vol. 67(10): str.819-25

### II-Poglavlja u knjizi

- Potpara Z, Duborija-Kovačević N. *Farmakopeja*. U: Duborija- Kovačević N i sar. *Oblici lijekova sa recepturom*. PRISMA- korporativne komunikacije, Podgorica, 2015. p.57-66. ISBN 978-9940-9314-4-4-5 COBISS.CG-ID 27254032
- Potpara Z, Bojović D. *Ljekoviti aktivni principi biljnih droga*. U: Duborija- Kovačević N i sar. *Oblici lijekova sa recepturom*. PRISMA- korporativne komunikacije, Podgorica, 2015. p.39-57. ISBN 978-9940-9314-4-4-5 COBISS.CG-ID 27254032

### III- Međunarodni kongresi, simpozijumi i seminari

- Dragana Marković, Ana Todorović, Zorica Potpara. *Modern Pharmaceutical forms with pulsatile drug release- Pulsincap* 37<sup>th</sup> International medical scientific congress in Ohrid. May 2014. ISBN 978-608-4596-59-2
- Jovanović-Djurašković M, Karadžić J, Potpara Z. *Development of Pharmacy in the History of Montenegro*. 40<sup>th</sup> International Congress for the History of Pharmacy, Berlin 2011; Pharmacy and Books, p. 92-3.
- Potpara Zorica, Janković Slobodan. *The mineral mud in dermocosmetics preparations in treatment of acne*. V Congress of pharmacy of Macedonia with International participation. Ohrid 2011. Macedonian pharmaceutical bulletin 57(suppl.) 2011. p.263.

- Marstijepović N., Kovacević D., Potpara Z. *Analysis of the samples of clays with location Montenegro on the microstructure of the sintered products*. 2<sup>th</sup> International samsonov Memorial Conference, „Materials Science of Refractory Compounds, Kyiv, 2010, Ukraina
- N. Marstijepović, D. Kovačević, Z. Potpara. *Comparison granulometric analysis sample illite-kaolinite clays on the microstructure of sintered product*. XIV International Clay Conference – Italy 2009, Book of abstract, Vol. II p. 562-3
- N. Marstijepović, Z. Potpara. *Analiza ugroženosti pri udesima i zaštita životne sredine*. Zbornik radova – Zaštita, Novi Sad, 2010., Srbija, p.271-80
- Z. Potpara, S. Vučurović, I. Arsić, V. Tadić. *Fitokozmetika i balneologija- mogućnost razvoja novih proizvoda za njegu i zaštitu kože*. IX Dani lekovitog bilja, 2008. Kosmaj. Zbornik radova, p.100-1

#### IV-Domaći kongresi, simpozijumi i seminari

- Snežana Pantović, Najdana Gligorović-Burhanović, Zorica Potpara, Nebojša Kavarić. *Antioksidativna odbrana i inflamacija u restenozni nakon perkutane koronarne intervencije*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.163-4
- Drljević Ivana, Lukač Džana, Pačarić Amina, Đurković Alisa, Potpara Zorica. *ALERGIJE- najčešći simptomi i uzročnici*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.220-1
- Lukač Džana, Drljević Ivana, Potpara Zorica. *Uloga farmaceuta u samomedikaciji*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.238-9
- Amina Kučević, Ana Žurić, Tijana Dabović, Zorica Potpara. *Racionalna upotreba antibiotika među studentima farmacije*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.234-5
- Šabotić Sabina, Anđelić Kristina, Koprivica Tijana, Potpara Zorica. *Upotreba dijetetskih suplemenata za smanjenje tjelesne mase*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.250-1
- Nikolić Marija, Cmiljanić Sladana, Potpara Zorica. *Primjena neopioidnih analgetika u Crnoj Gori*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.244-5
- Miomir Šoškić, Vanja Tadić, Dragica Bojović, Zorica Potpara, Zinaida Kalač, Anđela Drašković. *Uporedna hemijska analiza etarskih ulja izolovanih iz cvijeta lavande (Lavandulae flos, Lamiaceae) različitog geografskog porijekla*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik sažetaka, ISBN 978-9940-9314-3-8; p.183-5
- Šabotić Sabina, Anđelić Kristina, Koprivica Tijana, Potpara Zorica. *Use of dietary supplements for weight loss*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik radova
- Drljević Ivana, Lukač Džana, Pačarić Amina, Đurković Alisa, Potpara Zorica. *Allergies - the most common symptoms and causes*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik radova
- Amina Kučević, Ana Žurić, Tijana Dabović, Zorica Potpara. *The rational use of antibiotics among the students on faculty of pharmacy*. II Kongres farmaceuta sa međunarodnim učešćem, Bečići, 2015. Zbornik radova


- Lukač Džana, Drljević Ivana, Potpara Zorica. The role of pharmacist in self -- medication. II Kongres farmaceuta sa međunarodnim učešćem Bečići, 2015. Zbornik radova
- Nikolić Marija, Cmiljanić Sladana, Potpara Zorica. Use of non-opioid analgesics in Montenegro. II Kongres farmaceuta sa međunarodnim učešćem Bečići, 2015. Zbornik radova
- Potpara Zorica, Janković Slobodan. *Peloid u dermokozmetičkim preparatima*. I Kongres farmaceuta Crne Gore sa međunarodnim učešćem Bečići, 2011. Zbornik radova. 2011. p. 40-41
- Vojinović A, Šoškić M, Šarkinović E, Potpara Z. *Akne: prevalencija i faktori nastanka* I Kongres farmaceuta Crne Gore sa međunarodnim učešćem. Bečići, 2011. Zbornik radova. 160-161.
- Marstijepović N., Nikolić D., Potpara Z. *Mikroalge kao izvor energije*. I Međunarodna konferencija. Zaštita, ekologija, bezbjednost. Bar, Crna Gora, 2012. Zbornik radova.
- Ana Todorović, Dragana Marković, Zorica Potpara. *Modern pharmaceutical forms whit pulsatile drug release-Pulsincap®*. 37th International Medical Scientific Congress in Ohrid

#### V- Uvodno, objavljeno plenarno predavanje

- Zorica Potpara. *Farmaceutski fakultet u Podgorici-sadašnjost i perspektive*. II Kongres farmaceuta sa međunarodnim učešćem. Bečići, 2015. Zbornik sažetaka. ISBN 978-9940-9314-3-8.p.68-9
- Zorica Potpara, Željka Bešović, Majda Šahman-Zaimović. *Regulativa u oblasti lijekova u Crnoj Gori. Racionalna terapija*. 2017. Vol. 9, No.1,p:109-110. ISSN:1821-0538
- Zorica Potpara. *Generički lijekovi-dio zdravog rešenja*. V Medical konferencija sa međunarodnim učešćem. Bečići, Jun, 2018. Zbornik radova
- Zorica Potpara. *Primjena peloida u dermokozmetičkim preparatima u tretmanu akni i njezi kože*. I Konferencija "Značaj i uloga balneologije u rehabilitaciji inflamatornih stanja". Igalo, septembar 2018.

#### VI - Recenziranje

- *Serbian Journal of Experimental and Clinical Research*. ISSN 1820 -- 8665 . 1 rad .(M. Sovrlić and N Manojlović. Plants from the genus daphne: a review of its traditional uses, phytochemistry, biological and pharmacological activity)
- *Int J Pharm*. ISSN: 0378-5173 . 1 rad (J.Đuriš, Z.Đurić Modeling in the Quality by Design environment: regulatory requirements and recommendations for design space and control strategy applications)
- *Saudi Pharmaceutical Journal ( SPJ)*. ISSN: 1319-0164. 1 rad . Telmisartan-meglumine solid dispersions: influence of physico-chemical characteristics on telmisartan intrinsic dissolution



## УНИВЕРЗИТЕТ У БЕОГРАДУ

Адреса: Студентски трг 1, 11000 Београд, Република Србија  
Тел: 011 3207400; Факс: 011 2638818; E-mail: officebu@rect.bg.ac.rs

СЕНАТ УНИВЕРЗИТЕТА  
У БЕОГРАДУ

Београд, 16.07.2014. године  
06-01 Број: 61202-2484/3-14  
МЦ

На основу чл. 65. ст. 2. Закона о високом образовању ("Службени гласник РС", број 76/05, 100/07-аутентично тумачење, 97/08, 44/10 и 93/12), чл. 42. ст. 1. тач. 23. и чл. 43. ст. 4. Статута Универзитета у Београду ("Гласник Универзитета у Београду", број 162/11-пречишћени текст и 167/12), чл. 25. ст. 1. и ст. 2. тач. 1. Правилника о начину и поступку стицања звања и заснивања радног односа наставника Универзитета у Београду ("Гласник Универзитета у Београду", број 142/08, 150/09 и 160/11) и Критеријума за стицање звања наставника на Универзитету у Београду ("Гласник Универзитета у Београду", број 140/08, 144/08, 160/11, 161/11, 165/11), а на предлог Изборног већа Фармацеутског факултета, број: 998/1 од 15.05.2014. године и мишљења Већа научних области медицинских наука, број: 61202-2484/2-14 од 08.07.2014. године, Сенат Универзитета, на седници одржаној 16.07.2014. године, донео је

### О Д Л У К У

БИРА СЕ др Светлана Ибрић у звање редовног професора на Универзитету у Београду-Фармацеутски факултет, за ужу научну област Фармацеутска технологија.

### О б р а з л о ж е њ е

Фармацеутски факултет је дана 05.03.2014. године у листу „Послови“ објавио конкурс за избор у звање редовног професора, за ужу научну област Фармацеутска технологија, због истека изборног периода.

Извештај Комисије за припрему извештаја о пријављеним кандидатима стављен је на увид јавности дана 11.04.2014. године преко сајта и архиве Факултета.

На основу предлога Комисије за припрему извештаја о пријављеним кандидатима, Изборно веће Фармацеутског факултета, на седници одржаној дана 15.05.2014. године, донело је одлуку о утврђивању предлога да се кандидат др Светлана Ибрић изабере у звање редовног професора.

Фармацеутски факултет је дана 22.05.2014. године доставио Универзитету комплетан захтев за избор у звање на прописаним обрасцима.

Универзитет је комплетну документацију коју је доставио Факултет ставио на веб страницу Универзитета дана 30.06.2014. године.


13.4.2014. 21.7.2014  
01 998/3

Веће научних области медицинских наука, на седници одржаној дана 08.07.2014. године дало је мишљење да се др Светлана Ибрић може изабрати у звање редовног професора.

Сенат Универзитета, на седници одржаној дана 16.07.2014. године разматрао је захтев Фармацеутског факултета и утврдио да кандидат испуњава услове прописане чл. 64. и 65. Закона о високом образовању, чланом 124. Статута Универзитета у Београду, као и услове прописане Критеријумима за стицање звања наставника на Универзитету у Београду, па је донета одлука као у изречи.

ПРЕДСЕДНИК СЕНАТА

Ректор

  
Проф. др Владимир Бумбаширевић

Доставити:

- Факултету (2)
- архиви Универзитета
- сектору 06

**Dr sc. Svetlana Ibrić**

Zvanje: redovni profesor

Organizaciona jedinica: Katedra za farmaceutsku tehnologiju i kozmetologiju Farmaceutskog fakulteta u Beogradu

Telefon: +381 11 3951-371

Fax: +381 11 3972-840

Email: [svetlana.ibric@pharmacy.bg.ac.rs](mailto:svetlana.ibric@pharmacy.bg.ac.rs)

Svetlana Ibrić je diplomirala 1994. godine, magistrirala 1997. godine, a doktorirala 2002. godine na Farmaceutskom fakultetu Univerziteta u Beogradu. Zdravstvenu specijalizaciju iz farmaceutske tehnologije završila je 2005. godine. Izabrana je u zvanje redovnog profesora za naučnu oblast farmaceutska tehnologija 2014. godine. U periodu od 2012. godine do danas je na poziciji Prodekana za nauku i međunarodnu saradnju Farmaceutskog fakulteta.

2017. godine je od strane *Evropskog direktorata za kvalitet lekova* (EDQM) izabrana za eksperta i šefa radne grupe „*Powders WG*“ pri Evropskoj farmakopeji.

Rukovodilac je i osnivač **Centra za industrijsku farmaciju** (<http://ciff.emyspot.com/>) koji okuplja članove iz svih farmaceutskih kompanija u Srbiji i regionu, regulatornih tijela i univerziteta.

Član je *Komisije za stavljanje u promet humanih lekova* Agencije za lekove i medicinska sredstva Srbije (od 2010. godine do danas) i eksterni ekspert za procjenu dokumentacije o kvalitetu u sklopu dokumentacije za registraciju lijeka (od 2006. godine).

Rukovodilac je nacionalnog projekta “Razvoj proizvoda i tehnologija koje obezbjeđuju željeno oslobađanje ljekovite supstance iz čvrstih farmaceutskih oblika” finansiranog od strane Ministarstva prosvete, nauke i tehnološkog razvoja Republike Srbije, uz participaciju kompanija Hemofarm a.d. i Galenika a.d.

Rukovodilac je doktorskih studija – modul farmaceutska tehnologija, kao i akademske specijalizacije Industrijska farmacija.

Rukovodila je jednim međunarodnim bilateralnim projektom (period 2013.-2014. „*Application of machine learning tools in establishing a design space in solid dosage forms development*”, bilateralni projekat sa Republikom Njemačkom (koordinator sa njemačke strane: Prof. Dr. Peter Kleinebudde, Heinrich-Heine-University, Duesseldorf)).

Trenutno je član Upravnog odbora dva COST projekta: (a) 2015-2019 Simulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines (*SimInhale*) - COST Action MP1404 i (b) 2016-2020 European Network of Bioadhesion Expertise: Fundamental Knowledge to Inspire Advanced Bonding Technologies - COST Action CA15216.

Bila je mentor 12 odbranjenih doktorskih disertacija.

Istraživački interes je razvoj farmaceutskih oblika sa kontrolisanim oslobađanjem ljekovite supstance, primjena metoda mašinskog učenja u optimizaciji proizvoda i procesa, primjena QbD koncepta u razvoju farmaceutskih proizvoda/procesa. Ostvarila je značajnu međunarodnu saradnju sa istraživačkim timovima Laboratorije za industrijsku farmaciju Farmaceutskog fakulteta u Bazelu (dr Gabriele Betz), Farmaceutskog fakulteta Aristotelovog Univerziteta u Solunu (prof Kyriakos Kachrimanis), Farmaceutskog fakulteta Heinrich-Heine Univerziteta u Dizeldorfu (prof Peter Kleinebudde), Farmaceutskog fakulteta u Ljubljani (prof Julijana Kristl) i drugim.

2016. godine je bila predsjednik Centralno-evropskog simpozijuma iz farmaceutske tehnologije, koji je održan u Beogradu.

Do sada je objavila preko 200 radova i saopštenja, koautor je preko 10 poglavlja u monografijama međunarodnog značaja. Citirana je 760 puta (bez autocitata), a h-indeks je 16.

## BIBLIOGRAFIJA (RADOVI) MENTORA

1. S. Ibrić, M. Jovanović, Z. Đurić, J. Parojčić, Lj. Solomun, The application of generalized regression neural network (GRNN) in the modeling and optimization of aspirin extended release tablets with Eudragit® RS PO as matrix substance, *J. Controll. Rel.*, 82,213-222, 2002
2. Parojčić J, Ibrić S, Đurić Z, Jovanović M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation, *European Journal of Pharmaceutical Sciences*, 2007, 30 (3-4): 264-272
3. Solomun L., Ibric S., Boltic Z., Djuric Z, Stupar B. The impact of primary packaging on the quality of parenteral products, 2008, *Journal of Pharmaceutical and Biomedical Analysis* 48 (3), pp. 744-748
4. Djekic L, Ibric S, Primorac M. The application of artificial neural networks in the prediction of microemulsion phase boundaries in PEG-8 caprylic/capric glycerides based systems, 2008, *International Journal of Pharmaceutics* 361 (1-2), pp. 41-46
5. Parojčić J, Vasiljević D, Ibrić S, Djurić Z, Tablet disintegration and drug dissolution in viscous media: Paracetamol IR tablets, 2008, *International Journal of Pharmaceutics* 355 (1-2), pp. 93-99
6. Parojčić J, Karljiković-Rajić K, Đurić Z, Jovanović M, Ibrić S. Development of the Second-order Derivative UV Spectrophotometric Method for Direct Determination of Paracetamol in Urine Intended for Biopharmaceutical Characterisation of Drug Products, *Biopharm Drug Dispos.* 2003; 24: 309-314
7. B. Stanković, T. Jovanović, S. Mašić, Z. Korićanac, Use of Palladium (II) chloride as colourforming reagent in spectrophotometric determination of propylthiouracil in aqueous solutions and tablets, *Il Farmaco*, 51 (10), 679-682, 1996
8. S. Ibrić, M. Jovanović, Z. Đurić, J. Parojčić, Screening of parameters for in vitro drug release from enteric coated diclofenac sodium tablets, *Farmaceutski vestnik*, 48, 338-339, 1997
9. S. Ibrić, M. Jovanović, Z. Đurić, J. Parojčić, Influence of sodium chloride on the release of diclofenac sodium from enteric-coated tablets, *Pharm. Pharmacol. Lett.* 7(4), 181-183, 1997
10. J. Radovanović, Z. Đurić, M. Jovanović, S. Ibrić, M. Petrović: An attempt on establishing in vitro-in vivo correlation: case of paracetamol immediate release tablets, *Eur.J. Drug Metab. Pharmacokinet.*, 23, 33-40, 1998
11. S. Simović, J. Milić-Aškrić, G. Vuleta, S. Ibrić, M. Stupar, The influence of processing variables on performance of O/W emulsion gels based on polymeric emulsifier (Pemulen® TR-2NF), *International Journal of Cosmetic Science*, 21, 119-125, 1999
12. J. Parojčić, Z. Đurić, M. Jovanović, S. Ibrić, L. Nikolic: Influence of pH and Agitation Intensity on Drug Dissolution from Tablets Evaluated by Means of Factorial Design, *Pharm. Ind.*, 63, 774-779, 2001
13. Ibrić S, Jovanović M, Đurić Z, Parojčić J, Solomun Lj, Lučić B, Generalized regression neural networks in prediction of drug stability, *The Journal of Pharmacy and Pharmacology* 2007, 59 (5): 745-750
14. Parojčić J, Đurić Z, Jovanović M, Ibrić S, Kilibarda V, Jovanović D, Kovačević Ivan, Biopharmaceutical characterization of sustained release matrix tablets based on novel carbomer polymers: formulation and in vivo investigation, *European Journal of Drug Metabolism and Pharmacokinetics* 2005; 30 (1-2):99-104



15. Parojčić J, Đurić Z, Jovanović M, Ibrić S, Jovanović D. Influence of dissolution media composition on drug release and in-vitro/in-vivo correlation for paracetamol matrix tablets prepared with novel carbomer polymers; *The Journal of Pharmacy and Pharmacology* 2004, 56 (6): 735-741.
16. Parojčić J, Đurić Z, Jovanović M, Ibrić S. An investigation into the factors influencing drug release from hydrophilic matrix tablets based on novel carbomer polymers, *Drug Delivery* 2004, 11 (1): 59-65.
17. Ibrić S, Jovanović M, Đurić Z, Parojčić J, Petrović DS, Solomun Lj, Stupar B. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance, *AAPS PharmSciTech* 2003; 4 (1) Article 9
18. Ibrić S. Primena veštačkih neuronskih mreža u farmaceutskoj tehnologiji, Zadužbina Andrejević, Beograd, 2003
19. Ibrić S. Primena matematičke teorije eksperimenata u farmaceutskoj tehnologiji, Konstisi, Beograd, 2006
20. J. Parojčić, S. Ibrić, M. Jovanović, Z. Đurić: Lekoviti oblici u terapiji ulkusne bolesti, *Arh.Farm.* 48 (4) 323-341, 1998
21. J. Parojčić, Z. Đurić, M. Jovanović, S. Ibrić.: Biofarmaceutski sistem klasifikacije lekova i njegova primena u razvoju farmaceutskih preparata, *Arh.farm.* 51, 89-108, 2001
22. Parojčić J, Grbić S., Knežević M, Krsmanović S, Ibrić S, Đurić Z, Uticaj hrane na resorpciju lekova: osnovna razmatranja i mogućnost in vitro simulacije, *Arh farm* 2007; 57: 149-163
23. Ibrić S. Knežević M, Parojčić J, Đurić Z, Primena veštačkih neuronskih mreža u formulaciji farmaceutskih preparata, *Arh farm* 2007; 57: 399-414

**Dr sc. Svetlana Ibrić**

**Bibliografija**

- Kaljević O, Djuris J, Čalija B, Lavrič Z, Kristl J, **Ibrić S**. Application of miscibility analysis and determination of Soluplus solubility map for development of carvedilol-loaded nanofibers. *Int J Pharm* 2017; 533(2):445-454.
- Kovačević J, **Ibrić S**, Djuriš J, Klainebudde P, Application of the Design of Experiments in Optimization of Drug Layering of Pellets with an Insight into Drug Polymer Interactions. *Int J Pharm* 2016, 506, 312-319.
- Medarević Dj, Kachrimanis K, Djurić Z, **Ibrić S**. Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl- $\beta$ -cyclodextrin. *Eur J Pharm Sci.* 2015; 78:273-285.
- Krstić M, Popović M, Dobričić V, **Ibrić S**. Influence of Solid Drug Delivery System Formulation on Poorly Water-Soluble Drug Dissolution and Permeability. *Molecules.* 2015; 20:14684-14698.
- Djokić M, Kachrimanis K, Solomun L, Djuriš J, Vasiljević D, **Ibrić S**. A study of jet milling and spray drying process for the physicochemical and aerodynamic dispersion properties of amiloride HCl. *Powder Technol.* 2014; 262:170-176.
- Aleksić I, Djuriš J, **Ibrić S**, Parojčić J. An investigation into the usefulness of different empirical modeling techniques for better control of spray-on fluidized bed melt granulation. *Int J Pharm.* 2015; 496(2):627-635.
- Djuriš J, Nikolakakis I, **Ibrić S**, Djurić Z, Kachrimanis K. Preparation of Carbamazepine-Soluplus<sup>®</sup> solid dispersions by Hot-Melt Extrusion, and prediction of drug-polymer miscibility by thermodynamic model fitting. *Eur J Pharm Biopharm.* 2013; 84(1):228-237.
- Milović M, Djuriš J, Djekić L, Vasiljević D, **Ibrić S**. Characterization and evaluation of solid self-microemulsifying drug delivery systems with porous carriers as systems for improved carbamazepine release. *Int J Pharm.* 2012; 436(1-2):58-65.
- Petrović J, **Ibrić S**, Betz G, Đurić Z. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees. *Int J Pharm.* 2012; 428: 57-67.
- **Ibrić S**, Jovanović M, Djurić Z, Parojčić J, Solomun Lj. The application of generalized regression neural network (GRNN) in the modeling and optimization of aspirin extended release tablets with Eudragit<sup>®</sup> RS PO as matrix substance. *J. Controll. Rel.* 2002; 82: 213-222.



Univerzitet Crne Gore  
UNIVERSITY OF MONTENEGRO  
University of Montenegro

14.02.2020

broj 431

Na osnovu člana 72 stav 2 Zakona o visokom obrazovanju („Službeni list Crne Gore“ br 44/14, 47/15, 40/16, 42/17, 71/17, 55/18, 3/19, 17/19, 47/19) i člana 32 stav 1 tačka 9 Statuta Univerziteta Crne Gore, Senat Univerziteta Crne Gore na sjednici održanoj 10.02.2020. godine, donio je

### ODLUKU O IZBORU U ZVANJE

Dr Nataša Duborija Kovačević bira se u akademsko zvanje redovni profesor Univerziteta Crne Gore za oblast Farmakološka grupa medicinskih predmeta, na Medicinskom fakultetu Univerziteta Crne Gore, na neodređeno vrijeme.

SENAT UNIVERZITETA CRNE GORE  
PREDSJEDNIK

Prof. dr Đaniilo Nikolić, rektor

NATAŠA DUBORIJA-KOVAČEVIĆ, dr med., dr med. sci.  
Redovni profesor Farmakologije i Kliničke farmakologije



### CURRICULUM VITAE

**Adresa:** Medicinski fakultet Univerziteta Crne Gore  
Katedra za farmakologiju i kliničku farmakologiju  
Naselje Kruševac bb  
81000 Podgorica  
Crna Gora  
Tel.: ++ 382 20 412225 Mob. Tel.: ++ 382 67 227887  
Faks. br.: ++ 382 20 243842  
e-mail: [duborijan@ucg.ac.me](mailto:duborijan@ucg.ac.me)

**Datum i mjesto rođenja:** 10. oktobar 1973., Bijelo Polje, Crna Gora

#### Obrazovanje:

- Doktor nauka (2008) (Naučna oblast: Medicina,  
Naučna disciplina: Klinička farmakologija)  
Medicinski fakultet, Univerzitet u Novom Sadu, Srbija  
Doktorska disertacija: "Farmakoterapijske mogućnosti u liječenju  
benigne hiperplazije prostate: eksperimentalni i klinički aspekt" (Mentor doc. dr sci. Zdenko Tomić)
- Magistar nauka (2003) (Naučna oblast: Medicina  
Naučna disciplina: Klinička farmakologija i terapija)  
Medicinski fakultet, Univerzitet u Beogradu, Srbija  
Magistarski rad: "Analiza vanbolničke upotrebe lijekova u Crnoj  
Gori" (Mentor: Prof. dr. sci. Tomislav Kažić)
- Doktor medicine (1999)  
Medicinski fakultet, Univerzitet u Beogradu, Srbija (prosječna  
ocjena: 9,63/10)
- Osnovno studije medicine (1992-1999)  
Medicinski fakultet, Univerzitet u Beogradu, Srbija
- Gimnazija „Slobodan Škerović“ (1988-1992), Podgorica
- Osnovna škola „Branko Božović“ (1980-1988), Podgorica

#### Radno iskustvo:

- 2020 - Redovni profesor (šef katedre)  
Katedra za farmakologiju i kliničku farmakologiju, Medicinski fakultet Univerziteta Crne  
Gore, Podgorica
- 2015 - 2020 Vanredni profesor (šef katedre)

Katedra za farmakologiju i kliničku farmakologiju, Medicinski fakultet Univerziteta Crne Gore, Podgorica

- 2009 - 2015 Doцент (šof katedre)  
Katedra za farmakologiju i kliničku farmakologiju, Medicinski fakultet Univerziteta Crne Gore, Podgorica
- 2000 - 2009 Saradnik na nastavi  
Katedra za farmakologiju i kliničku farmakologiju, Medicinski fakultet Univerziteta Crne Gore, Podgorica
- 1999-2000 Pripravnički staž za doktora medicine  
Medicinski fakultet Univerziteta u Beogradu

Stipendije, nagrade, priznanja:

- EACPT (European Association for Clinical Pharmacology and Therapeutics) stipendija za učešće na EACPT Focus Meeting-u 2016, Opalija, Hrvatska, 6-9 oktobra 2016.
- Stipendija Federacije evropskih toksikologa i evropskih toksikoloških društava (EUROTOX) za učešće na 8. Kongresu jugoistočne Europe o metabolizmu i toksičnosti ksenobiotika (XEMET 2010), Solun, Grčka, 1-5 oktobra 2010.
- EACPT stipendija za učešće na 9. kongresu Evropskog udruženja za kliničku farmakologiju i terapiju, Edinburgh, Scotland, 12-16 marta 2009.
- Nominacija za najbolju prezentaciju postera "FINALIST POSTER AWARD" za rad pod nazivom „Je li propisivanje antibiotika za najčešće infekcije u primarnoj zdravstvenoj zaštiti racionalno ili ne?“, 9. godišnji Evropski kongres međunarodnog društva farmakoeonomije i Istraživanja ishoda (ISPOR), 28-31 oktobar 2006, Kopenhagen, Danska
- Nominacija za najbolju prezentaciju dana za istraživanje pod nazivom „Troškovi farmakološkog liječenja esencijalne hipertenzije u Crnoj Gori: Može li biti jeftinije?“, VIII konferencija Evropskog udruženja za kliničku farmakologiju i terapiju (EACPT), 28.08. 01.09.2007., Amsterdam, Holandija
- EACPT stipendija za učešće na 7. kongresu EACPT-a u Poznanu, Poljska, 2005
- Stipendija EACPT za učešće u Četvrtoj evropskoj ljetnjoj školi za kliničku farmakologiju i terapiju, Vršac, Srbija, 16-20 septembar 2006. godine.
- EACPT stipendija za učešće na 8. kongresu EACPT-a u Amsterdamu, Holandija, 28. avgust-01. septembar 2007.
- stipendija World University Service Austria (WUS-Austrija) za učešće na 18. Evropskoj radionici o metabolizmu lijekova u Valensiji, Španija, 16-20 septembar 2002. (AMG br. 37/02)
- Individual mobility grant (IMG) Evropske komisije za obrazovanje i kulturu (TEMPUS) za učešće na Kongresu Evropskog društva za hipertenziju, Milano, Italija, 2003 (Finansijski sporazum br. IMG03-FRM1001)
- Stipendija Vlade Crne Gore za talentovane studente (1993-1999)
- Diploma "Luča" (1992)

Dodatni profesionalni angažman:

- član Komisije za izdavanje dozvole za stavljanje lijeka u promet u Crnogorskoj Agenciji za lijekove i medicinska sredstva (CALIMS) (2009 - )
- eksterni ekspert Crnogorske Agencije za lijekove i medicinska sredstva (CALIMS) za procjenu farmakološke i toksikološke dokumentacije u postupku izdavanja dozvola za stavljanje lijeka u promet (2009 - )
- član Nacionalne interdisciplinarnе komisije za kontrolu rezistencije na antibiotike (NIKRA) i učesnik u izradi Nacionalnog programa za kontrolu rezistencije na antibiotike za razdoblje 2012 - 2016 (2012 -2017)
- član Komisije za izradu Liste lijekova koji se izdaju na ljekarski recept koje refundira Fond za zdravstveno osiguranje Crne Gore, koju je formiralo Ministarstvo zdravlja Crne Gore (2015 - 2016)
- član Odbora za unapređenje kvaliteta na Univerzitetu Crne Gore (2017 - )
- član Odbora za monitoring master studija na Univerzitetu Crne Gore (2017 - )
- nacionalni ekspert Savjeta Evrope za akademski integritet (Horizontalna akcija EU / Savjet Evrope „Kvalitetno obrazovanje za sve“ u Crnoj Gori, Lot 1: Jačanje kapaciteta visokoškolskih ustanova u Crnoj Gori u promovisanju etičkih vrijednosti i očuvanju akademskog integriteta) (2020 - )

### Recenzentska aktivnost

(April 2019 - ) Recenzent međunarodnog časopisa *Frontiers in Pharmacology (Section of Pharmaceutical Medicine and Outcomes Research)*, 25/232 (Q1), IF:3,845, ISSN: 1663-9812

### Međunarodni strukturni i naučnoistraživački projekti:

- Edukator u projektu *Montenegro Health System Improvement*. (Contract No: SAM-MHSIP-3918 YF-CS-IC-05-B16.5-D-20 signed on September 28, 2006) (2006-2011)
- Koordinator mobilnosti u TEMPUS projektu JEP-40106-2005 *Reform of Curriculum Content to Undergraduate Medical Education at University of Montenegro* (2006-2009, budžet u iznosu od 390000 EUR)
- Mobility coordinator in project *Erasmus Mundus/Western Balkans (ERAWEB II)* (2013-2017)
- Koordinator istraživanja za Klinički centar Crne Gore u projektu *Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS)* (Vodeći istraživači: Herman Goossens, University Hospital of Antwerp, Belgium i Dilip Nathwani, Ninewells Hospital and Medical School, Dundee, Scotland) (2014- 2015)
- Učesnik u projektu CCNURCA: 544169-TEMPUS-1-2013-1-BE-TEMPUS-JPCR: *„Competency based Curriculum Reform in Nursing and Caring in Western Balkan Universities”* (2013-2016)
- Koordinator istraživanja za Crnu Goru u projektu *Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS)* (Vodeći istraživači: Herman Goossens, University Hospital of Antwerp, Belgium i Dilip Nathwani, Ninewells Hospital and Medical School, Dundee, Scotland) (2017)
- Član Upravnog odbora i istraživač u međunarodnom naučnoistraživačkom projektu COST ACTION 15105: *European Medicines Shortages Research Network - addressing supply problems to patients (Medicines Shortages)* (Action Chair: Tomasz Bochenek, Jagellonian University, Institute for Public Health, Cracow, Poland) (2016-2020)
- Nacionalni ekspert za akademski integritet u projektu EU/Council of Europe Horizontal facility action *“Quality education for all” in Montenegro, Lot 1: Strengthen capacities of HEIs in Montenegro to promote ethical values and safeguard academic integrity* (2020 - )

### Bilateralni naučnoistraživački projekti:

- Aktivni istraživač u projektu *“Comparative study of the impact of poverty on malnutrition and obesity, nutritional and lifestyle habits in school children in Podgorica and Osijek”* (CROMONT) (2016-2017)

### Nacionalni naučnoistraživački projekti:

- Rukovodilac nacionalnog inovativnog projekta *“Nestlašice ljekova u Crnoj Gori kao dio kompleksnog globalnog problema – dinamika, uzroci i moguća rješenja (Drug – Short – Mont)”*, Ministarstvo nauke Crne Gore, (2018-2019)
- Aktivni istraživač u projektu *„Investigation of obesity and poverty in children in Montenegro – clinical, pathophysiological, biochemical and preventive aspects”* (2012-2014)
- Aktivni istraživač u projektu *„Mladi naučnici i etika u XXI vijeku”*, Crnogorska akademija nauka i umjetnosti, Centar mladih naučnika (2013).

**Članstvo u naučnim i stručnim udruženjima:**

- Evropsko udruženje za kliničku farmakologiju i terapiju (EACPT)
- Srpsko farmakološko društvo
- Centar mladih naučnika Crnogorske akademije nauka i umjetnosti (do navršene 40. godine)
- Udruženje ljekara Crne Gore

**Vještine:**

- Odlične komunikacione, leaderske i organizacione vještine stečene kroz dugogodišnji pedagoški rad, realizaciju nacionalnih i međunarodnih projekata i stručno angažovanje
- Značajno iskustvo i prepoznat uspjeh u domaćim i međunarodnim naučnim i strukturnim projektima
- Odlične pedagoške i mentorske vještine, uključujući analizu, sintezu, različite vrste izlaganja, raspravu, odgovaranje na pitanje, ispitivanje
- PC (Microsoft Office)
- Engleski (tečno)

**Lični status:** Udata, dvoje djece

PROF. DR NATAŠA DUBORIJA-KOVAČEVIĆ  
IN EXTENSO RADovi INDEKSIRANI U BAZAMA SCI, SCI Exp i CC:

1. Duborija-Kovačević N, Tomić Z. *Did a reform strategy in drug management improve doctors' prescribing habits in Montenegro: the example for the cardiovascular drugs.* Vojnosanit Pregl 2006 May;63(5): 451-6.
2. Duborija-Kovačević N. *The outpatient use of beta lactam antibiotics in Montenegro before the introduction of new reform strategy on drug market.* Srp Arh Celok Lek 2006;134(5-6):224-8.
3. Duborija-Kovačević N, Jakovljević V, Saha A, Tomić Z. *Anti-nociceptive and anti-inflammatory properties of 5 alpha-reductase inhibitor finasteride in experimental animals.* Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):181-6.
4. Duborija-Kovacevic N, Jakovljevic V, Saha A, Tomic Z, Pajovic B, Perovic D. *Tolerability and Toxicity o Lipidosterolic Extract of American Dwarf Palm *Serenoa Repens* in Wistar Rats: Well-known Extract. New Insight.* Eur Rev Medical Pharmacol Sci 2011; 15(11):1311-7.
5. Duborija-Kovacevic N, Martinovic M. *Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries.* Multidiscip Respir Med 2012;7:12.
6. Potpara Z, Duborija-Kovačević N (vodjeći autor). *Effects of the peloid cream from the Montenegrin adriatic coast on skin humidity, transepidermal water loss and erythema index, examined with skin bioengineering in vivo methods.* Farmacia 2012;60(4):p.524-34.
7. Martinovic M, Belojevic G, Evans GW, Asanin B, Lausevic D, Duborija-Kovacevic N, Samardzic M, Jaksic M, Pantovic S. *Blood pressure among rural Montenegrin children in relation to poverty and gender.* Eur J Pub Health 2014;24(3):385-9.
8. Radnic B, Radojevic N, Vucinic J and Duborija-Kovacevic N (vodjeći autor). *The association between pro-arrhythmic agents and aortic stenosis in young adults: is it sufficient to clarify the sudden unexpected deaths?* Cardiology in the Young 2016; Page 1-7.
9. Duborija-Kovacevic N, Shavrina K. *New findings on the pharmacodynamic actions of olive oil: our contribution to better evidence about its remedial properties.* Progress in Nutrition (accepted for publication in November 2016, in press).
10. Potpara Z, Duborija-Kovačević N. *Effects of the peloid cream from the Montenegrin adriatic coast on skin humidity, transepidermal water loss and erythema index, examined with skin bioengineering in vivo methods.* Farmacia 2012;60(4):p.524-34.
11. Versporten, A., Zarb, P., Caniaux, L., ... , Duborija-Kovačević, N., et al. (2018). *Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey.* The Lancet global health, 6(6), pp.e619-e629.
12. Bochenek, T., Abilova, V., Alkan, A., ... , Duborija-Kovačević, N., et al. (2018). *Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries.* Frontiers in pharmacology, 8, p.942.
13. Duborija-Kovačević, N., Martinović, M., Belojević, G., Laušević, D., Ašanin, B. (2019) *Maternal education, health profession and cigarette smoking are decisive factors for self-medication in children by parents.* Acta Pharmaceutica. Published online July 8, 2019 pp:1-7.
14. Duborija-Kovacevic, N., & Tomic, Z. (2019). *Kidney, skeletal muscle and myocardium as potential target sites of Pygeum africanum toxicity in Wistar rats.* Revista internacional de andrologia, 17(1), 8-14.
15. N Miljković, B Godman, M Kovačević, ... , N Duborija-Kovacevic, T Bochenek, I Huys, B Miljković *Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications.* Front. Pharmacol., 26 March 2020
16. Banjari I, Martinovic M, Belojevic G, Asanin B, Duborija-Kovacevic N, et al. *Poverty and other correlates of obesity and underweight among 7-year-olds from Croatia and Montenegro.* Public Health, Vol 182, Maj 2020, pp.64-69.



CRNA GORA

OPŠTINA GLAVNI GRAD PODGORICA

IZVOD IZ MATIČNOG REGISTRA VJENČANIH

U matičnom registru vjenčanih koji se vodi za Opštinu DONJA GORICA  
 pod rednim brojem 120 za godinu 2018 izvršen je upis zaključenja braka:

Mjesto zaključenja braka	PODGORICA	
Dan, mjesec i godina zaključenja braka	28.(dvadesetosmi) oktobar 2018. godine	
Ime	SUPRUG	SUPRUGA
	MOMIR	GORDANA
Prezime	STANOJEVIĆ	BOLJEVIĆ
Jedinstveni matični broj	2907983210026	2711989217993
Dan, mjesec i godina rođenja	29.07.1983.	27.11.1989.
Mjesto i opština / grad i država rođenja	PODGORICA, CRNA GORA	PODGORICA, CRNA GORA
Državljanstvo	CRNE GORE	CRNE GORE
Prebivalište i adresa stana	PODGORICA, BRATSTVA I JEDINSTVA 77	PODGORICA, VOJVODANSKA 8
Ime i prezime roditelja supružnika	Otac	NIKOLA STANOJEVIĆ
	Majka	MILOSAVA STANOJEVIĆ rod. PAVIĆEVIĆ
Izjava supružnika o njihovom prezimenu	STANOJEVIĆ	BUDISLAV BOLJEVIĆ
ZDENKA BOLJEVIĆ rod. MILATOVIĆ		
STANOJEVIĆ		
Naknadni upis i pribilješke:		

Dana

20.02.2023.god.

U

PODGORICI



JELA KOVAČEVIĆ

(potpis matičara)

Primljeno:	19.05.2023		
Org. jed.	Broj	Prilog	Vrijednost
Med.	736		

UNIVERZITET CRNE GORE  
VIJEĆU MEDICINSKOG FAKULTETA  
Komisiji za doktorske studije

**PREDMET:** Zahtjev za ocjenu doktorske disertacije

Poštovani,

U skladu sa Pravilima studiranja na doktorskim studijama Univerziteta Crne Gore, podnosim zahtjev za ocjenu doktorske disertacije pod nazivom:

**„Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju“**

Završetkom izrade doktorske disertacije i objavljivanjem rada u časopisu sa SCI/SCIE liste koji sadrži djelove istraživanja sprovedenih u okviru izrade ove doktorske disertacije, ispunila sam uslove za njenu predaju.

Ovim putem se obraćam Komisiji za doktorske studije Medicinskog fakulteta da inicira predlog Komisije za ocjenu doktorske disertacije.

Uz zahtjev prilažem:

- pisanu saglasnost mentora sa predajom doktorske disertacije
- 7 štampanih primjeraka doktorske disertacije
- CD sa cjelokupnim sadržajem doktorske disertacije u PDF formatu i publikovani rad koji sadrži djelove istraživanja sprovedenih u okviru izrade doktorske disertacije
- fotokopiju rada objavljenog kao rezultat doktorske teze i Izvoda iz matičnog registra vjenčanih kao obrazloženje navodenja udatog prezimena na objavljenom radu
- pisanu izjavu o autorstvu (Prilog 1 iz Uputstva o oblikovanju doktorske disertacije)
- pisanu izjavu o istovjetnosti štampane i elektronske verzije rada (Prilog 2 iz Uputstva o oblikovanju doktorske disertacije)
- pisanu izjavu o korišćenju (Prilog 3 iz Uputstva o oblikovanju doktorske disertacije)

S poštovanjem,

Dr pharm Gordana Boljević



U Podgorici, 19.05.2023. godine

UNIVERTITET CRNE GORE  
MEDICINSKI FAKULTET

Na osnovu Odluke Senata Univerziteta Crne Gore br. 03-1728/2 od 03.07.2018. godine, imenovana sam za mentora za izradu doktorske disertacije kandidatkinje dr pharm. Gordane Boljević. U fazi predaje doktorske disertacije na pregled i ocjenu, u skladu sa Pravilima doktorskih studija Univerziteta Crne Gore, dajem:

### SAGLASNOST

Saglasna sam da kandidatkinja dr pharm. Gordana Boljević može da preda doktorsku disertaciju pod nazivom „Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju“ na pregled i ocjenu.

U Beogradu, 30.03.2023. godine

Mentor

Prof. dr Svetlana Ibrić



### Izjava o autorstvu

Potpisani-a Gordana Boljević

Broj indeksa/upisa:

### Izjavljujem


da je doktorska disertacija pod naslovom

„Primjena odabranih tehnika 3D štampe u izradi tableta za personalizovanu terapiju“

- rezultat sopstvenog istraživačkog rada,
- da predložena disertacija ni u cjelini ni u djelovima nije bila predložena za dobijanje bilo koje diplome prema studijskim programima drugih ustanova visokog obrazovanja, da su rezultati korektno navedeni, i
- da nijesam povrijedila autorska i druga prava intelektualne svojine koja pripadaju trećim licima.

U Podgorici, 19.05.2023.

Potpis doktoranda



UNIVERZITET CRNE GORE

MEDICINSKI FAKULTET

Broj: F36/1-2

Podgorica 30.06.2023. godine.

Uvidom u službenu evidenciju ,izdaje se

**POTVRDA**

**Prof. dr Svetlana Ibrić**, redovni profesor Farmaceutskog fakulteta Univerziteta u Beogradu, nije u radnom odnosu na Medicinskom fakultetu Univerziteta Crne Gore.

Potvrda se izdaje kao prilog obrascu D2 za kandidata dr pharm Gordanu Stanojević , i u druge svrhe se ne može koristiti.

ŠEF STUDENTSKE SLUŽBE  
*Sonja Vukićević*  
Sonja Vukićević, diplomirani pravnik

